

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

10

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 7/50, C11D 3/00		A1	(11) International Publication Number: WO 98/55093
			(43) International Publication Date: 10 December 1998 (10.12.98)
(21) International Application Number: PCT/US98/10971		(74) Agents: REED, T., David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217 (US).	
(22) International Filing Date: 29 May 1998 (29.05.98)			
(30) Priority Data: 08/868,783 4 June 1997 (04.06.97) US 08/868,695 4 June 1997 (04.06.97) US 08/868,982 4 June 1997 (04.06.97) US 08/969,049 12 November 1997 (12.11.97) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant: THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US).		Published <i>With international search report.</i>	
(72) Inventors: BEERSE, Peter, William ; 8874 Pollard Place, Maineville, OH 45039 (US). MORGAN, Jeffrey, Michael ; 8575 Highmont Drive, Springboro, OH 45066 (US). BAIER, Kathleen, Grieshop ; 3660 Hanley Road, Cincinnati, OH 45247 (US). CEN, Wei ; 8936 Cypresspoint Lane, Cincinnati, OH 45249 (US). BAKKEN, Theresa, Anne ; 11956 Britesilks Lane, Cincinnati, OH 45249 (US). CLAPP, Mannie, Lee ; 5042 Lexington Court, Mason, OH 45040 (US). WARREN, Raphael ; 6715 West Farm Acres Drive, Amberly Village, OH 45237 (US).			
(54) Title: MILD, RINSE-OFF ANTIMICROBIAL LIQUID CLEANSING COMPOSITIONS			
(57) Abstract <p>The present invention relates to a rinse-off antimicrobial cleansing composition characterized in that it comprises from 0.001 % to 5 % of an antimicrobial active, from 1 % to 80 % of an anionic surfactant, from 0.1 % to 12 % of a proton donating agent; and from 3 % to 98.899 % of water, wherein the composition is adjusted to a pH of from 3.0 to 6.0, wherein the rinse-off antimicrobial cleansing composition has a Gram Positive Residual Effectiveness Index of greater than 1.8, and wherein the rinse-off antimicrobial cleansing composition has a Mildness Index of greater than 0.3. The present invention also relates to a rinse-off antimicrobial cleansing composition which has a Gram Positive Residual Effectiveness Index of greater than 1.8. The present invention also relates to a rinse-off antimicrobial cleansing composition which has a one-wash Immediate Germ Reduction Index of greater than 2.5 and a Mildness Index of greater than 0.3. The invention also relates to a rinse-off antimicrobial cleansing composition which has a Ten-wash Immediate Germ Reduction Index of greater than 2.8 and a Mildness Index of greater than 0.3. The invention also encompasses methods for cleansing skin and providing residual effectiveness versus Gram positive bacterial using these products.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

WO 98/55093

PCT/US98/10971

1

MILD, RINSE-OFF ANTIMICROBIAL LIQUID CLEANSING COMPOSITIONS

TECHNICAL FIELD

The present invention relates to mild, rinse-off, personal cleansing compositions which provide enhanced antimicrobial effectiveness. Specifically, the rinse-off cleansing compositions of the invention provide previously unseen residual effectiveness against transient Gram negative bacteria, previously unseen levels of residual effectiveness against Gram positive bacteria, provide improved immediate germ reduction on the skin compared to prior art compositions. These rinse-off cleansing compositions are also mild to the skin.

BACKGROUND OF THE INVENTION

Human health is impacted by many microbial entities. Inoculation by viruses and bacteria cause a wide variety of sicknesses and ailments. Media attention to cases of food poisoning, strep infections, and the like is increasing public awareness of microbial issues.

It is well known that the washing of hard surfaces, food (e.g. fruit or vegetables) and skin, especially the hands, with antimicrobial or non-medicated soap, can remove many viruses and bacteria from the washed surfaces. Removal of the viruses and bacteria is due to the surfactancy of the soap and the mechanical action of the wash procedure. Therefore, it is known and recommended that the people wash frequently to reduce the spread of viruses and bacteria.

Bacteria found on the skin can be divided into two groups: resident and transient bacteria. Resident bacteria are Gram positive bacteria which are established as permanent microcolonies on the surface and outermost layers of the skin and play an important, helpful role in preventing the colonization of other, more harmful bacteria and fungi.

Transient bacteria are bacteria which are not part of the normal resident flora of the skin, but can be deposited when airborne contaminated material lands on the skin or when contaminated material is brought into physical contact with it. Transient bacteria are typically divided into two subclasses: Gram positive and Gram negative. Gram positive bacteria include pathogens such as *Staphylococcus aureus*, *Streptococcus pyogenes* and *Clostridium botulinum*. Gram negative bacteria include pathogens such as *Salmonella*, *Escherichia coli*, *Klebsiella*, *Haemophilus*, *Pseudomonas aeruginosa*, *Proteus* and *Shigella dysenteriae*. Gram negative bacteria are generally distinguished from Gram positive by an additional protective cell membrane which generally results in the Gram negative bacteria being less susceptible to topical antibacterial actives.

Antimicrobial cleansing products have been marketed in a variety of forms for some time. Forms include deodorant soaps, hard surface cleaners, and surgical disinfectants. These traditional rinse-off antimicrobial products have been formulated to provide bacteria removal

WO 98/55093

PCT/US98/10971

2

during washing. Antimicrobial liquid cleansers are disclosed in U.S. Patent Numbers: 4,847,072, Bissett et al., issued July 11, 1989, 4,939,284, Degenhardt, issued July 3, 1990 and 4,820,698, Degenhardt, issued April 11, 1989, all of which are incorporated herein by reference.

Previously marketed formulations of Head & Shoulders® Dandruff Shampoo, marketed until 1994, comprised anionic surfactants, an antibacterial active, and citric acid as a pH adjuster. Head & Shoulders® controlled *Pityrosorum ovale* fungus, which causes dandruff. PCT application WO 92/18100, Keegan et al., published October 29, 1992 ("Keegan") and PCT application WO 95/32705, Fujiwara et al., published December 7, 1995 ("Fujiwara") teach liquid skin cleansers comprising mild surfactants, antibacterial agents and acidic compounds to buffer the pH, which provide improved germ hostility. However, the use of the acid compounds for only pH adjustment therein, result in compositions which do not deliver the undissociated acid required to provide residual effectiveness versus Gram negative bacteria, or to provide improved levels of residual effectiveness versus Gram positive bacteria, or to provide improved levels of immediate germ removal upon use. This situation is compounded in Keegan and Fujiwara by the preference of mild surfactants, including nonionic surfactants.

Some of these antimicrobial products, especially the hard surface cleaners and surgical disinfectants, utilize high levels of alcohol and/or harsh surfactants which have been shown to dry out and irritate skin tissues. Ideal personal cleansers should gently cleanse the skin, cause little or no irritation, and not leave the skin overly dry after frequent use and preferably should provide a moisturizing benefit to the skin.

U.S. Patent Number 3,141,821, issued to Compeau July 21, 1964 and Irgasan DP 300 (Triclosan®) technical literature from Ciba-Giegy, Inc., "Basic Formulation for Hand Disinfection 89/42/01" set forth antibacterial skin cleansers compositions which could provide any of the benefits provided by the compositions of the present invention using certain anionic surfactants, antimicrobial actives and acids. However, the selection, therein, of highly active surfactants results in personal cleansing compositions which are drying and harsh to the skin.

Given the health impacts of Gram negative bacteria like *Salmonella*, *Escherichia coli* and *Shigella* and of Gram positive bacteria like *Staphylococcus aureus*, *Streptococcus pyogenes* and *Clostridium botulinum*, it would be highly desirable to formulate antimicrobial cleansing compositions which provide previously unseen residual effectiveness versus these Gram negative bacteria, or which provide improved residual effectiveness versus these Gram positive bacteria, or which provide improved immediate germ reduction upon washing, and which are mild to the skin. Existing consumer products have been unable to achieve the combination of both the mildness benefits and bacterial effectiveness.

Applicants have found that rinse-off antimicrobial cleansing compositions which provide such mildness and such bacterial effectiveness can be formulated by using known antimicrobial

WO 98/55093

PCT/US98/10971

3

actives in combination with specific organic and/or inorganic acids as proton donating agents, and specific anionic surfactants, all of which are deposited on the skin. The deposited proton donating agent and anionic surfactant enhance the selected active, to provide a new level of hostility to bacteria contacting the skin.

SUMMARY OF THE INVENTION

The present invention relates to a rinse-off antimicrobial cleansing composition characterized in that it comprises from 0.001% to 5% of an antimicrobial active; from 1% to 80% of an anionic surfactant; from 0.1% to 12% of a proton donating agent; and from 3% to 98.899% of water; wherein the composition is adjusted to a pH of from 3.0 to 6.0. The rinse-off antimicrobial cleansing compositions further have a Gram Negative Residual Effectiveness Index of greater than 0.3; and a Mildness Index of greater than 0.3.

The present invention also relates to a rinse-off antimicrobial cleansing composition which has a Gram Positive Residual Effectiveness Index of greater than 1.8; and wherein the rinse-off antimicrobial cleansing composition has a Mildness Index of greater than 0.3.

The present invention also relates to a rinse-off antimicrobial cleansing composition which has a One-wash Immediate Germ Reduction Index of greater than 2.5 and a Mildness Index of greater than 0.3. The invention also relates to a rinse-off antimicrobial cleansing composition which has a Ten-wash Immediate Germ Reduction Index of greater than 2.8 and a Mildness Index of greater than 0.3.

The present invention also relates to methods for cleansing and for decreasing the spread of transient Gram positive bacteria using the rinse-off antimicrobial cleansing compositions described herein.

DETAILED DESCRIPTION OF THE INVENTION

The rinse-off antimicrobial cleansing compositions of the present invention are highly efficacious for cleansing surfaces, especially the skin, and are mild to the skin. They provide a residual antimicrobial effectiveness versus transient Gram negative or Gram positive bacteria, or provide improved immediate germ reduction during cleansing.

The term "rinse-off" is used herein to mean that the compositions of the present invention are used in a context whereby the composition is ultimately rinsed or washed from the treated surface, (e.g. skin or hard surfaces) either after or during the application of the product.

The term "antimicrobial cleansing composition" as used herein means a composition suitable for application to a surface for the purpose of removing dirt, oil and the like which additionally controls the growth and viability of transient Gram positive bacteria. Preferred embodiments of the present invention are cleansing compositions suitable for use on the human skin.

WO 98/55093

PCT/US98/10971

4

By "residual effectiveness" it is meant that bacteria growth on a surface is controlled for some period of time following the washing/rinsing process.

The compositions of the present invention can also be useful for treatment of acne. As used herein "treating acne" means preventing, retarding and/or arresting the process of acne formation in mammalian skin.

The compositions of the invention can also potentially be useful for providing an essentially immediate (i.e., acute) visual improvement in skin appearance following application of the composition to the skin. More particularly, the compositions of the present invention are useful for regulating skin condition, including regulating visible and/or tactile discontinuities in skin, including but not limited to visible and/or tactile discontinuities in skin texture and/or color, more especially discontinuities associated with skin aging. Such discontinuities may be induced or caused by internal and/or external factors. Extrinsic factors include ultraviolet radiation (e.g., from sun exposure), environmental pollution, wind, heat, low humidity, harsh surfactants, abrasives, and the like. Intrinsic factors include chronological aging and other biochemical changes from within the skin.

Regulating skin condition includes prophylactically and/or therapeutically regulating skin condition. As used herein, prophylactically regulating skin condition includes delaying, minimizing and/or preventing visible and/or tactile discontinuities in skin. As used herein, therapeutically regulating skin condition includes ameliorating, e.g., diminishing, minimizing and/or effacing, such discontinuities. Regulating skin condition involves improving skin appearance and/or feel, e.g., providing a smoother, more even appearance and/or feel. As used herein, regulating skin condition includes regulating signs of aging. "Regulating signs of skin aging" includes prophylactically regulating and/or therapeutically regulating one or more of such signs (similarly, regulating a given sign of skin aging, e.g., lines, wrinkles or pores, includes prophylactically regulating and/or therapeutically regulating that sign).

"Signs of skin aging" include, but are not limited to, all outward visibly and tactilely perceptible manifestations as well as any other macro or micro effects due to skin aging. Such signs may be induced or caused by intrinsic factors or extrinsic factors, e.g., chronological aging and/or environmental damage. These signs may result from processes which include, but are not limited to, the development of textural discontinuities such as wrinkles, including both fine superficial wrinkles and coarse deep wrinkles, skin lines, crevices, bumps, large pores (e.g., associated with adnexal structures such as sweat gland ducts, sebaceous glands, or hair follicles), scaliness, flakiness and/or other forms of skin unevenness or roughness, loss of skin elasticity (loss and/or inactivation of functional skin elastin), sagging (including puffiness in the eye area and jowls), loss of skin firmness, loss of skin tightness, loss of skin recoil from deformation, discoloration (including undereye circles), blotching, sallowness, hyperpigmented skin regions

All percentages and ratios used herein, unless otherwise indicated, are by weight and all measurements made are at 25°C, unless otherwise designated. The invention hereof can comprise, consist of, or consist essentially of, the essential as well as optional ingredients and components described therein.

The rinse-off antimicrobial cleansing compositions of the present invention comprise an antimicrobial active, an anionic surfactant, and a proton donating agent. These components are selected so that the efficacy and mildness requirements hereinafter defined for the compositions herein are met. The selection of each component is necessarily dependent on the selection of each of the other components. For example, if a weak acid is selected as the proton donating agent, then in order to realize an efficacious composition, either a more biologically active (but possibly less mild) surfactant must be employed, and/or a high level of acid within the prescribed range must be used and/or a particularly efficacious active must be employed and/or a higher level of deposition within the prescribed range must be employed. Similarly, if a mild, but nonefficacious surfactant is employed, then a stronger acid and/or a high level of acid and/or a high level of deposition aid may be necessary to realize an efficacious composition. If a harsh surfactant is utilized, then a mildness agent may have to be utilized or a lipophilic skin moisturizer ingredient may have to be employed as the deposition aid. Guidelines for the selection of the individual components are provided herein.

The rinse-off antimicrobial cleansing composition of the present invention comprises from 0.001% to 5%, preferably from 0.01% to 2%, more preferably from 0.05% to 1.5% and more preferably from 0.1% to 1.0%, by weight of the antimicrobial cleansing composition, of an antimicrobial active. The exact amount of antibacterial active to be used in the compositions will depend on the particular active utilized since actives vary in potency. Non-cationic actives are required in order to avoid interaction with the anionic surfactants of the invention.

- Pyrithiones, especially the zinc complex (ZPT)
- Octopirox®
- Dimethyldimethylol Hydantoin (Glydant®)
- Methylchloroisothiazolinone/methylisothiazolinone (Kathon CG®)
- Sodium Sulfite
- Sodium Bisulfite

WO 98/55093

PCT/US98/10971

6

Imidazolidinyl Urea (Germall 115®)
Diazolidinyl Urea (Germall II®)
Benzyl Alcohol
2-Bromo-2-nitropropane-1,3-diol (Bronopol®)
Formalin (formaldehyde)
Iodopropenyl Butylcarbamate (Polyphase P100®)
Chloroacetamide
Methanamine
Methyldibromonitrile Glutaronitrile (1,2-Dibromo-2,4-dicyanobutane or Tektamer®)
Glutaraldehyde
5-bromo-5-nitro-1,3-dioxane (Bronidox®)
Phenethyl Alcohol
o-Phenylphenol/sodium o-phenylphenol
Sodium Hydroxymethylglycinate (Suttocide A®)
Polymethoxy Bicyclic Oxazolidine (Nuosept C®)
Dimethoxane
Thimersal
Dichlorobenzyl Alcohol
Captan
Chlorphenenesin
Dichlorophene
Chlorbutanol
Glyceryl Laurate
Halogenated Diphenyl Ethers
 2,4,4'-trichloro-2'-hydroxy-diphenyl ether (Triclosan® or TCS)
 2,2'-dihydroxy-5,5'-dibromo-diphenyl ether
Phenolic Compounds
 Phenol
 2-Methyl Phenol
 3-Methyl Phenol
 4-Methyl Phenol
 4-Ethyl Phenol
 2,4-Dimethyl Phenol
 2,5-Dimethyl Phenol
 3,4-Dimethyl Phenol
 2,6-Dimethyl Phenol
 4-n-Propyl Phenol
 4-n-Butyl Phenol
 4-n-Amyl Phenol
 4-tert-Amyl Phenol
 4-n-Hexyl Phenol
 4-n-Heptyl Phenol
Mono- and Poly-Alkyl and Aromatic Halophenols
 p-Chlorophenol
 Methyl p-Chlorophenol
 Ethyl p-Chlorophenol
 n-Propyl p-Chlorophenol
 n-Butyl p-Chlorophenol
 n-Amyl p-Chlorophenol
 sec-Amyl p-Chlorophenol

WO 98/55093

PCT/US98/10971

7

n-Hexyl p-Chlorophenol
 Cyclohexyl p-Chlorophenol
 n-Heptyl p-Chlorophenol
 n-Octyl p-Chlorophenol
 o-Chlorophenol
 Methyl o-Chlorophenol
 Ethyl o-Chlorophenol
 n-Propyl o-Chlorophenol
 n-Butyl o-Chlorophenol
 n-Amyl o-Chlorophenol
 tert-Amyl o-Chlorophenol
 n-Hexyl o-Chlorophenol
 n-Heptyl o-Chlorophenol
 o-Benzyl p-Chlorophenol
 o-Benzyl-m-methyl p-Chlorophenol
 o-Benzyl-m, m-dimethyl p-Chlorophenol
 o-Phenylethyl p-Chlorophenol
 o-Phenylethyl-m-methyl p-Chlorophenol
 3-Methyl p-Chlorophenol
 3,5-Dimethyl p-Chlorophenol
 6-Ethyl-3-methyl p-Chlorophenol
 6-n-Propyl-3-methyl p-Chlorophenol
 6-iso-Propyl-3-methyl p-Chlorophenol
 2-Ethyl-3,5-dimethyl p-Chlorophenol
 6-sec-Butyl-3-methyl p-Chlorophenol
 2-iso-Propyl-3,5-dimethyl p-Chlorophenol
 6-Diethylmethyl-3-methyl p-Chlorophenol
 6-iso-Propyl-2-ethyl-3-methyl p-Chlorophenol
 2-sec-Amyl-3,5-dimethyl p-Chlorophenol
 2-Diethylmethyl-3,5-dimethyl p-Chlorophenol
 6-sec-Octyl-3-methyl p-Chlorophenol
 p-Chloro-m-cresol
 p-Bromophenol
 Methyl p-Bromophenol
 Ethyl p-Bromophenol
 n-Propyl p-Bromophenol
 n-Butyl p-Bromophenol
 n-Amyl p-Bromophenol
 sec-Amyl p-Bromophenol
 n-Hexyl p-Bromophenol
 Cyclohexyl p-Bromophenol
 o-Bromophenol
 tert-Amyl o-Bromophenol
 n-Hexyl o-Bromophenol
 n-Propyl-m,m-Dimethyl o-Bromophenol
 2-Phenyl Phenol
 4-Chloro-2-methyl phenol
 4-Chloro-3-methyl phenol
 4-Chloro-3,5-dimethyl phenol
 2,4-Dichloro-3,5-dimethylphenol

" WO 98/55093

PCT/US98/10971

8

3,4,5,6-Terabromo-2-methylphenol

5-Methyl-2-pentylphenol

4-Isopropyl-3-methylphenol

Para-chloro-meta-xlenol (PCMX)

Chlorothymol

Phenoxyethanol

Phenoxyisopropanol

5-Chloro-2-hydroxydiphenylmethane

Resorcinol and its Derivatives

Resorcinol

Methyl Resorcinol

Ethyl Resorcinol

n-Propyl Resorcinol

n-Butyl Resorcinol

n-Amyl Resorcinol

n-Hexyl Resorcinol

n-Heptyl Resorcinol

n-Octyl Resorcinol

n-Nonyl Resorcinol

Phenyl Resorcinol

Benzyl Resorcinol

Phenylethyl Resorcinol

Phenylpropyl Resorcinol

p-Chlorobenzyl Resorcinol

5-Chloro 2,4-Dihydroxydiphenyl Methane

4'-Chloro 2,4-Dihydroxydiphenyl Methane

5-Bromo 2,4-Dihydroxydiphenyl Methane

4' -Bromo 2,4-Dihydroxydiphenyl Methane

Bisphenolic Compounds

2,2'-Methylene bis (4-chlorophenol)
 2,2'-Methylene bis (3,4,6-trichlorophenol)
 2,2'-Methylene bis (4-chloro-6-bromophenol)
 bis (2-hydroxy-3,5-dichlorophenyl) sulphide
 bis (2-hydroxy-5-chlorobenzyl)sulphide

Benzoic Esters (Parabens)

Methylparaben
 Propylparaben
 Butylparaben
 Ethylparaben
 Isopropylparaben
 Isobutylparaben
 Benzylparaben
 Sodium Methylparaben
 Sodium Propylparaben

Halogenated Carbanilides

3,4,4'-Trichlorocarbanilides (Triclocarban® or TCC)
 3-Trifluoromethyl-4,4'-dichlorocarbanilide
 3,3',4-Trichlorocarbanilide

Another class of antibacterial agents, which are useful in the present invention, are the so-called "natural" antibacterial actives, referred to as natural essential oils. These actives derive their names from their natural occurrence in plants. Typical natural essential oil antibacterial actives include oils of anise, lemon, orange, rosemary, wintergreen, thyme, lavender, cloves, hops, tea tree, citronella, wheat, barley, lemongrass, cedar leaf, cedarwood, cinnamon, fleagrass, geranium, sandalwood, violet, cranberry, eucalyptus, vervain, peppermint, gum benzoin, basil, fennel, fir, balsam, menthol, ocmea origanum, *Hydastis carradensis*, *Berberidaceae daceae*, *Ratanhiae* and *Curcuma longa*. Also included in this class of natural essential oils are the key chemical components of the plant oils which have been found to provide the antimicrobial benefit. These chemicals include, but are not limited to anethol, catechole, camphene, thymol, eugenol, eucalyptol, ferulic acid, farnesol, hinokitiol, tropolone, limonene, menthol, methyl salicylate, carvacol, terpineol, verbenone, berberine, ratanhia extract, caryophellene oxide, citronellic acid, curcumin, nerolidol and geraniol.

Additional active agents are antibacterial metal salts. This class generally includes salts of metals in groups 3b-7b, 8 and 3a-5a. Specifically are the salts of aluminum, zirconium, zinc, silver, gold, copper, lanthanum, tin, mercury, bismuth, selenium, strontium, scandium, yttrium, cerium, praseodymium, neodymium, promethum, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium and mixtures thereof.

Preferred antimicrobial agents for use herein are the broad spectrum actives selected from the group consisting of Triclosan®, Triclocarban®, Octopirox®, PCMX, ZPT, natural essential oils and their key ingredients, and mixtures thereof. The most preferred antimicrobial active for use in the present invention is Triclosan®.

WO 98/55093

PCT/US98/10971

10

B. ANIONIC SURFACTANT

Liquid embodiments of the rinse-off antimicrobial cleansing compositions of the present invention comprise from 1% to 80%, preferably from 3% to 50%, and more preferably from 5% to 25%, based on the weight of the personal cleansing composition, of an anionic surfactant. Solid bar embodiments of the present invention preferably comprise from 10% to 70%, and more preferably from 20% to 60% of the anionic surfactant. Without being limited by theory, it is believed that the anionic surfactant disrupts the lipid in the cell membrane of the bacteria. The particular acid used herein reduces the negative charges on the cell wall of the bacteria, crosses through the cell membrane, weakened by the surfactant, and acidifies the cytoplasm of the bacteria. The antimicrobial active can then pass more easily through the weakened cell wall, and more efficiently poison the bacteria.

Nonlimiting examples of anionic lathering surfactants useful in the compositions of the present invention are disclosed in McCutcheon's, Detergents and Emulsifiers, North American edition (1990), published by The Manufacturing Confectioner Publishing Co.; McCutcheon's, Functional Materials, North American Edition (1992); and U.S. Patent No. 3,929,678, to Laughlin et al., issued December 30, 1975, all of which are incorporated by reference.

A wide variety of anionic surfactants are potentially useful herein. Nonlimiting examples of anionic lathering surfactants include those selected from the group consisting of alkyl and alkyl ether sulfates, sulfated monoglycerides, sulfonated olefins, alkyl aryl sulfonates, primary or secondary alkane sulfonates, alkyl sulfosuccinates, acyl taurates, acyl isethionates, alkyl glycerylether sulfonate, sulfonated methyl esters, sulfonated fatty acids, alkyl phosphates, acyl glutamates, acyl sarcosinates, alkyl sulfoacetates, acylated peptides, alkyl ether carboxylates, acyl lactylates, anionic fluorosurfactants, and mixtures thereof. Mixtures of anionic surfactants can be used effectively in the present invention.

Anionic surfactants for use in the cleansing compositions include alkyl and alkyl ether sulfates. These materials have the respective formulae R^1O-SO_3M and $R^1(CH_2H_4O)_x-O-SO_3M$, wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl group from 8 to 24 carbon atoms, x is 1 to 10, and M is a water-soluble cation such as ammonium, sodium, potassium, magnesium, triethanolamine, diethanolamine and monoethanolamine. The alkyl sulfates are typically made by the sulfation of monohydric alcohols (having from 8 to 24 carbon atoms) using sulfur trioxide or other known sulfation technique. The alkyl ether sulfates are typically made as condensation products of ethylene oxide and monohydric alcohols (having from 8 to 24 carbon atoms) and then sulfated. These alcohols can be derived from fats, e.g., coconut oil or tallow, or can be synthetic. Specific examples of alkyl sulfates which may be used in the cleanser compositions are sodium, ammonium, potassium, magnesium, or TEA salts

WO 98/55093

PCT/US98/10971

11

of lauryl or myristyl sulfate. Examples of alkyl ether sulfates which may be used include ammonium, sodium, magnesium, or TEA laureth-3 sulfate.

Another suitable class of anionic surfactants are the sulfated monoglycerides of the form $R^1CO-O-CH_2-C(OH)H-CH_2-O-SO_3M$, wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl group from 8 to 24 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium, magnesium, triethanolamine, diethanolamine and monoethanolamine. These are typically made by the reaction of glycerin with fatty acids (having from 8 to 24 carbon atoms) to form a monoglyceride and the subsequent sulfation of this monoglyceride with sulfur trioxide. An example of a sulfated monoglyceride is sodium cocomonoglyceride sulfate.

Other suitable anionic surfactants include olefin sulfonates of the form R^1SO_3M , wherein R^1 is a mono-olefin having from 12 to 24 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium, magnesium, triethanolamine, diethanolamine and monoethanolamine. These compounds can be produced by the sulfonation of alpha olefins by means of uncomplexed sulfur trioxide, followed by neutralization of the acid reaction mixture in conditions such that any sultones which have been formed in the reaction are hydrolyzed to give the corresponding hydroxyalkanesulfonate. An example of a sulfonated olefin is sodium C_{14}/C_{16} alpha olefin sulfonate.

Other suitable anionic surfactants are the linear alkylbenzene sulfonates of the form $R^1-C_6H_4-SO_3M$, wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl group from 8 to 24 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium, magnesium, triethanolamine, diethanolamine and monoethanolamine. These are formed by the sulfonation of linear alkyl benzene with sulfur trioxide. An example of this anionic surfactant is sodium dodecylbenzene sulfonate.

Still other anionic surfactants suitable for this cleansing composition include the primary or secondary alkane sulfonates of the form R^1SO_3M , wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl chain from 8 to 24 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium, magnesium, triethanolamine, diethanolamine and monoethanolamine. These are commonly formed by the sulfonation of paraffins using sulfur dioxide in the presence of chlorine and ultraviolet light or another known sulfonation method. The sulfonation can occur in either the secondary or primary positions of the alkyl chain. An example of an alkane sulfonate useful herein is alkali metal or ammonium C_{13} - C_{17} paraffin sulfonates.

Still other suitable anionic surfactants are the alkyl sulfosuccinates, which include disodium N-octadecylsulfosuccinamate; diammonium lauryl sulfosuccinate; tetrasodium N-(1,2-

WO 98/55093

PCT/US98/10971

12

dicarboxyethyl)-N-octadecylsulfosuccinate; diamyl ester of sodium sulfosuccinic acid; dihexyl ester of sodium sulfosuccinic acid; and dioctyl esters of sodium sulfosuccinic acid.

Also useful are taurates which are based on taurine, which is also known as 2-aminoethanesulfonic acid. Examples of taurates include N-alkyltaurines such as the one prepared by reacting dodecylamine with sodium isethionate according to the teaching of U.S. Patent 2,658,072 which is incorporated herein by reference in its entirety. Other examples based of taurine include the acyl taurines formed by the reaction of n-methyl taurine with fatty acids (having from 8 to 24 carbon atoms).

Another class of anionic surfactants suitable for use in the cleansing composition are the acyl isethionates. The acyl isethionates typically have the formula $R^1CO-O-CH_2CH_2SO_3M$ wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl group having from 10 to 30 carbon atoms, and M is a cation. These are typically formed by the reaction of fatty acids (having from 8 to 30 carbon atoms) with an alkali metal isethionate. Nonlimiting examples of these acyl isethionates include ammonium cocoyl isethionate, sodium cocoyl isethionate, sodium lauroyl isethionate, and mixtures thereof.

Still other suitable anionic surfactants are the alkylglyceryl ether sulfonates of the form $R^1-OCH_2-C(OH)H-CH_2-SO_3M$, wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl group from 8 to 24 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium, magnesium, triethanolamine, diethanolamine and monoethanolamine. These can be formed by the reaction of epichlorohydrin and sodium bisulfite with fatty alcohols (having from 8 to 24 carbon atoms) or other known methods. One example is sodium cocoglyceryl ether sulfonate.

Other suitable anionic surfactants include the sulfonated fatty acids of the form $R^1-CH(SO_4)-COOH$ and sulfonated methyl esters of the form $R^1-CH(SO_4)-CO-O-CH_3$, where R^1 is a saturated or unsaturated, branched or unbranched alkyl group from 8 to 24 carbon atoms. These can be formed by the sulfonation of fatty acids or alkyl methyl esters (having from 8 to 24 carbon atoms) with sulfur trioxide or by another known sulfonation technique. Examples include alpha sulphonated coconut fatty acid and lauryl methyl ester.

Other anionic materials include phosphates such as monoalkyl, dialkyl, and trialkylphosphate salts formed by the reaction of phosphorous pentoxide with monohydric branched or unbranched alcohols having from 8 to 24 carbon atoms. These could also be formed by other known phosphorylation methods. An example from this class of surfactants is sodium mono or dilaurylphosphate.

Other anionic materials include acyl glutamates corresponding to the formula $R^1CO-N(COOH)-CH_2CH_2-CO_2M$ wherein R^1 is a saturated or unsaturated, branched or unbranched

WO 98/55093

PCT/US98/10971

13

alkyl or alkenyl group of 8 to 24 carbon atoms, and M is a water-soluble cation. Nonlimiting examples of which include sodium lauroyl glutamate and sodium cocoyl glutamate.

Other anionic materials include alkanoyl sarcosinates corresponding to the formula $R^1\text{CON}(\text{CH}_3)\text{-CH}_2\text{CH}_2\text{-CO}_2\text{M}$ wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl or alkenyl group of 10 to 20 carbon atoms, and M is a water-soluble cation. Nonlimiting examples of which include sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, and ammonium lauroyl sarcosinate.

Other anionic materials include alkyl ether carboxylates corresponding to the formula $R^1\text{-(OCH}_2\text{CH}_2)_x\text{-OCH}_2\text{-CO}_2\text{M}$ wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl or alkenyl group of 8 to 24 carbon atoms, x is 1 to 10, and M is a water-soluble cation. Nonlimiting examples of which include sodium laureth carboxylate.

Other anionic materials include acyl lactylates corresponding to the formula $R^1\text{CO-[O-CH(CH}_3\text{)-CO]}_x\text{-CO}_2\text{M}$ wherein R^1 is a saturated or unsaturated, branched or unbranched alkyl or alkenyl group of 8 to 24 carbon atoms, x is 3, and M is a water-soluble cation. Nonlimiting examples of which include sodium cocoyl lactylate.

Other anionic materials include the carboxylates, nonlimiting examples of which include sodium lauroyl carboxylate, sodium cocoyl carboxylate, and ammonium lauroyl carboxylate. Anionic flourosurfactants can also be used.

Any counter cation, M, can be used on the anionic surfactant. Preferably the counter cation is selected from the group consisting of sodium, potassium, ammonium, monoethanolamine, diethanolamine, and triethanolamine. More preferably the counter cation is ammonium.

Three factors must be taken into account when selecting the surfactant or surfactants to be employed in the antibacterial cleansing compositions herein: 1) the activity of the surfactant molecule at the cell membrane of the bacteria; 2) the solubility characteristics of the selected active in the surfactant; and 3) the mildness of the surfactant insofar as it affects the Mildness Index (hereinafter described) for the antimicrobial composition.

Biological Activity/Mildness of Surfactant

In general, the higher the biological activity of the surfactant, the more residual effectiveness is provided by the composition comprising the surfactant. Typically, however, the biological activity of a surfactant and the mildness of a surfactant are inversely proportional; the higher the biological activity of the surfactant, the harsher the surfactant and the lower the biological activity of the surfactant, the milder the surfactant. Whether a biologically active, but harsh surfactant or a mild, but biologically inactive surfactant is desired will, of course, depend on (or influence) the selection of the other components.

For surfactant compositions which are mixtures of surfactants rather than pure surfactants (this includes "commercial grade" surfactants which typically comprise mixtures of entities with different chain lengths and potentially have higher levels of impurities), the Microtox Response Index for any individual surfactant component is not a reliable measurement of biological activity or mildness. In the case of mixtures, the Microtox Index of each individual component can be determined and the weighted average used as the Index for the mixture if all the individual components of the mixture are known. If the individual components of a mixture are not known, then the primary head group and chain lengths of the surfactant mixture are better indicators of biological activity/mildness.

Anionic surfactants or mixtures of surfactants with a chain length primarily in the range of from 8 to 24 carbon atoms, preferably primarily from 10 to 18 carbon atoms and most preferably primarily from 12 to 16 carbon atoms are preferred from the standpoint of high biological activity. As used herein "primarily" means at least 50%. From a standpoint of mildness, it is preferable to minimize C12.

From the standpoint of biological activity, it is preferred that the head group of the anionic surfactant be less than 15 Angstroms, preferably less than 10 Angstroms, and more preferably less than 7 Angstroms. The "head group" is defined as the hydrophilic portion (non-hydrocarbon) of the anionic surfactant, measured from the first polar atom to the end of the molecule. The head group size is estimated from the Van der Waals radius of the atoms and the configuration of the surfactant molecule. Head groups with sizes less than 7 Angstroms include sulfates, sulfonates, and phosphates. From the standpoint of mildness, it is preferred that the head group size is greater than 7 Angstroms, and preferably greater than 10 Angstroms. Head groups with sizes greater than 10 Angstroms include ethoxylated sulfates, glyceryl ether sulfonates, and isethionates. It is believed that as the head group size increases, more stearic

WO 98/55093

PCT/US98/10971

15

hindrance at the cell wall prevents disruption by the surfactant and, thus, biological activity is decreased and mildness is increased.

The mildness of a surfactant or mixture of surfactants can also be determined by a number of other known, conventional methods for measuring surfactant mildness. For example, the Barrier Destruction Test set forth in T. J. Franz, J. Invest. Dermatol., 1975, 64, pp. 190-195 and in U.S. Patent 4,673,525 to Small et al; issued June 16, 1987, both of which are herein incorporated by reference, is a way of measuring mildness of surfactants. In general, the milder the surfactant, the less skin barrier that is destroyed in the barrier destruction test. Skin barrier destruction is measured by relative amount of radiolabeled water which passes from the test solution through the skin epidermis into the physiological buffer contained in the diffusate chamber. Surfactants having a Relative Skin Barrier Penetration Value of as close to zero as possible up to 75 are considered mild for purposes herein. Surfactants having a Relative Skin Barrier Penetration Value of greater than 75 are considered harsh for purposes herein.

Solubility slope of Antimicrobial Active in Anionic Surfactant

Preferred anionic surfactants are also selected, in part, based on the ability of the surfactant to deposit the antimicrobial active onto the skin. Surfactants for use herein must have sufficient solubility to carry the active and yet the solubility cannot be so high that the active is held in solution during use, resulting in no active being deposited to the skin. It has been found that this balance is best measured by the slope of the curve of the solubility of the antimicrobial active versus the concentration of the surfactant in water. This slope, hereafter referred to as the solubility slope, K, is determined by the test method hereinafter described in the Analytical Methods Section.

Preferred anionic surfactants of the present invention comprise a solubility slope, K, of less than 0.60, preferably less than 0.40, more preferably less than 0.25 and most preferably less than 0.10.

The rinse-off antimicrobial cleansing compositions of the present invention preferably deposit from 0.01 $\mu\text{g}/\text{cm}^2$ to 100 $\mu\text{g}/\text{cm}^2$, more preferably from 0.1 $\mu\text{g}/\text{cm}^2$ to 50 $\mu\text{g}/\text{cm}^2$ and most preferably from 1 $\mu\text{g}/\text{cm}^2$ to 20 $\mu\text{g}/\text{cm}^2$ of antimicrobial active onto the skin.

In order for the personal cleansing compositions herein to be effective, both the biological activity of the surfactant and the solubility of the particular active employed in the surfactant must be taken into account.

For example, ammonium lauryl sulfate, ALS, is very biologically active (Microtox Index = 1.0) but has a relatively high solubility slope ($K = 0.3$). Compositions comprising ALS are capable of providing very effective residual antibacterial effectiveness due to its activity, even with lower levels of antibacterial active and proton donating agent. However, in order to deposit the active on the skin (which is required to meet the efficacy requirements described

WO 98/55093

PCT/US98/10971

16

herein), higher levels of active will be required as a result of the high solubility slope. Moreover, compositions containing ALS may require the addition of cosurfactants or polymers, described herein in the Optional Ingredient Section, to achieve most preferred mildness levels for the present invention.

A selection of ammonium laureth-3 sulfate (Microtox = 120 and $K = 0.5$) as a surfactant will result in compositions which are very mild, but which would require higher levels of proton donating agent and antimicrobial active in order to achieve the residual effectiveness of the present invention.

Paraffin sulfonate, a commercial grade surfactant sold under the name Hastapur SAS® from Hoechst Celanese, with a small head group and average chain length of 15.5 ($K = 0.1$) is a relatively active surfactant and provides very high deposition of the active. Compositions comprising lower levels of active and acid can be used with higher levels of paraffin sulfonate, where the surfactant provides a larger component of residual effectiveness. Alternately, compositions comprising lower levels of paraffin sulfonate can be combined with higher levels of active to achieve a mild and effective composition. Moderate levels of active can be used with paraffin sulfonate, since its solubility index indicates that such compositions will have very high deposition of the active.

Nonlimiting examples of preferred anionic surfactants useful herein include those selected from the group consisting of sodium and ammonium alkyl sulfates and ether sulfates having chain lengths of predominantly 12 and 14 carbon atoms, olefin sulfates having chain lengths of predominantly 14 and 16 carbon atoms, and paraffin sulfonates having chain lengths of from 13 to 17 carbon atoms, and mixtures thereof. Especially preferred for use herein is ammonium and sodium lauryl sulfate; ammonium and sodium myristyl sulfate; ammonium and sodium laureth-1, laureth-2, laureth-3, and laureth-4 sulfate; ammonium and sodium, C14-C16 olefin sulfonates; C13-C17 paraffin sulfonates, and mixtures thereof.

Non-anionic surfactants of the group consisting of nonionic surfactants, cationic surfactants, amphoteric surfactants and mixtures thereof, have been found to actually reduce residual effectiveness benefits when used with anionic surfactants at high levels. This is most evident in the case of cationic and amphoteric surfactants where it is believed that these surfactants interfere (charge-charge interaction) with the anionic surfactant's ability to disrupt of the lipid in the cell membrane. The ratio of the amount of these other surfactants to the amount of anionic surfactant should be less than 1:1, preferably less than 1:2, and more preferably less than 1:4.

The rinse-off antimicrobial cleansing compositions of the present invention preferably do not comprise hydrotropic sulfonates, particularly salts of terpenoids, or mono- or binuclear aromatic compounds such as sulfonates of camphor, toluene, xylene, cumene and naphthene.

WO 98/55093

PCT/US98/10971

17

C. PROTON DONATING AGENT

The rinse-off antimicrobial cleansing compositions of the present invention comprise from 0.1% to 12%, preferably from 0.5% to 10%, more preferably from 1% to 7.5%, and most preferably from 2.5% to 5%, based on the weight of the personal cleansing composition, of a proton donating agent. By "proton donating agent" it is meant any acid compound or mixture thereof, which results in the presence of undissociated acid on the skin after use. Proton donating agents can be organic acids, including polymeric acids, mineral acids or mixtures thereof.

Organic Acids

Proton donating agents which are organic acids remain at least partially undissociated in the neat composition and remain so when the compositions are diluted during washing and rinsing. The organic acid proton donating agent must have at least one pKa value below 5.5. These organic proton donating agents can be added directly to the composition in the acid form or can be formed by adding the conjugate base of the desired acid and a sufficient amount of a separate acid strong enough to form the undissociated acid from the base.

Biological Activity Index of Organic Acids

Preferred organic proton donating agents are selected based on their biological activity. This activity is represented by a Biological Activity Index, Z, which is defined as:

$$Z = 1 + 0.25pK_{a1} + 0.42\log P.$$

The biological activity index combines the dissociation characteristics and the hydrophobicity of the acid. It is critical that the undissociated proton donating agent of the composition be deposited on the skin to reduce the negative charge on the cell wall. The acid's dissociation constant, pK_{a1} , is indicative of the chemical's proton donating capacity relative to the pH of the medium in which it is incorporated. Since more undissociated acid is preferable in the composition, acids with higher pKa's are generally more preferred for a given product pH. The octanol-water partition coefficient, P, represents the tendency of materials in solution to prefer either oils or water. It essentially is a measure of hydrophobic nature of a material in solution: the higher the partition coefficient, the more oil soluble, and less water soluble, the material. Since it is desired that the dissolved acids in the compositions come out of the aqueous cleanser upon application, deposit on the oil-based skin and remain during rinsing, organic acids with higher octanol-water partition coefficients are more preferred.

Preferred organic proton donating agents of the rinse-off antimicrobial cleansing compositions of the present invention have a biological activity index greater than 0.5, preferably greater than 1.0, more preferably greater than 1.5 and most preferably greater than 2.0.

Mineral Acids

WO 98/55093

PCT/US98/10971

18

Proton donating agents which are mineral acids will not remain undissociated in the neat composition or when the compositions are diluted during washing and rinsing. Despite this, it has been found that mineral acids can be effective proton donating agents for use herein. Without being limited by theory, it is believed that the strong mineral acids, protonate the carboxylic and phosphatidyl groups in proteins of the skin cells, thereby providing *in-situ* undissociated acid. These proton donating agents can only be added directly to the composition in the acid form.

pH

It is critical to achieving the benefits of the invention that the undissociated acid from the proton donating agent (deposited or formed *in-situ*) remain on the skin in the protonated form. Therefore, the pH of the rinse-off antimicrobial cleansing compositions of the present invention must be adjusted to a sufficiently low level in order to either form or deposit substantial undissociated acid on the skin. The pH of the compositions should be adjusted and preferably buffered to have a range of from 3.0 to 6.0, preferably from 3.0 to 5.0 and more preferably from 3.5 to 4.5.

A non-exclusive list of examples of organic acids which can be used as the proton donating agent are adipic acid, tartaric acid, citric acid, maleic acid, malic acid, succinic acid, glycolic acid, glutaric acid, benzoic acid, malonic acid, salicylic acid, gluconic acid, polymeric acids, their salts, and mixtures thereof. A non-exclusive list of examples of mineral acid for use herein are hydrochloric, phosphoric, sulfuric and mixtures thereof.

Polymeric acids are especially preferred acids for use herein from the standpoint that they cause less stinging to the skin than other acids, they can have less of a negative impact on lather than other acids and they can contribute to a draggy rinse feel which is preferred by some consumers. As used herein, the term "polymeric acid" refers to an acid with repeating units of carboxylic acid groups joined together into one chain. Suitable polymeric acids can include homopolymers, copolymers and terpolymers, but must contain at least 30 mole% carboxylic acid groups. Specific examples of suitable polymeric acids useful herein include straight-chain poly(acrylic) acid and its copolymers, both ionic and nonionic, (e.g., maleic-acrylic, sulfonic-acrylic, and styrene-acrylic copolymers), those cross-linked polyacrylic acids having a molecular weight of less than 250,000, preferably less than 100,000 poly (α -hydroxy) acids, poly (methacrylic) acid, and naturally occurring polymeric acids such as carageenic acid, carboxy methyl cellulose, and alginic acid. Straight-chain poly(acrylic) acids are especially preferred for use herein.

D. WATER

Liquid rinse-off antimicrobial cleansing compositions of the present invention comprise from 35% to 98.899%, preferably from 45% to 98%, more preferably from 55% to 97.5%, and

WO 98/55093

PCT/US98/10971

19

most preferably from 65% to 95.99% water. Solid bar embodiments of the present invention preferably comprise from 2% to 25%, more preferably from 3% to 20% and most preferably from 5% to 15% water.

Liquid rinse-off antimicrobial cleansing compositions of the present invention, preferably have an apparent or neat viscosity of from 500 cps to 60,000 cps at 26.7°C, preferably 5,000 to 30,000 cps. The term "viscosity" as used herein means the viscosity as measured by a Brookfield RVTDCP with a spindle CP-41 at 1 RPM for 3 minutes, unless otherwise specified. The "neat" viscosity is the viscosity of the undiluted liquid cleanser.

E. PREFERRED OPTIONAL INGREDIENTS

Mildness Enhancers

In order to achieve the mildness required of the present invention, optional ingredients to enhance the mildness to the skin can be added. These ingredients include cationic and nonionic polymers, co-surfactants, moisturizers and mixtures thereof. Polymers useful herein include polyethylene glycols, polypropylene glycols, hydrolyzed silk proteins, hydrolyzed milk proteins, hydrolyzed keratin proteins, guar hydroxypropyltrimonium chloride, polyquats, silicone polymers and mixtures thereof. When used, the mildness enhancing polymers comprise from 0.1% to 1%, preferably from 0.2% to 1.0%, and more preferably from 0.2% to 0.6%, by weight of the rinse-off antimicrobial cleansing composition, of the composition. Co-surfactants useful herein include nonionic surfactants such as the Genapol® 24 series of ethoxylated alcohols, POE(20) sorbitan monooleate (Tween® 80), polyethylene glycol cocoate and Pluronic® propylene oxide/ethylene oxide block polymers, and amphoteric surfactants such as alkyl betaines, alkyl sultaines, alkyl amphotacetates, alkyl amphodiacetates, alkyl amphopropionates, and alkyl amphodipropionates. When used, the mildness enhancing cosurfactants comprise from 20% to 70%, preferably from 20% to 50%, by weight of the anionic surfactant, of the cleansing composition.

Deposition Aids

A deposition aid is also preferably employed in the rinse-off antimicrobial cleansing compositions herein. It has been found that compositions which contain a deposition aid of the type hereinafter described have improved antibacterial efficacy compared to compositions which do not contain one. Additionally, the especially preferred lipid skin moisturizing agent provides a moisturizing benefit to the user of the personal cleansing product when the lipophilic skin moisturizing agent is deposited to the user's skin.

When used in the liquid, rinse-off antimicrobial personal cleansing compositions herein, the deposition aid comprises from 0.1% to 30%, preferably from 1% to 30% more preferably from 3% to 25%, most preferably from 5% to 25% of the cleansing composition. The deposition aid employed herein is one that increases the deposition of the antimicrobial active or

WO 98/55093

PCT/US98/10971

20

the proton donating agent on the skin by at least 20%, preferably by at least 30%, more preferably at least 50%.

Suitable deposition aids for use herein include, for example, lipophilic skin moisturizing agents, cationic polymers, nonionic polymers, zeolites, clays and mixtures thereof. One of the reasons why cationic polymers are believed to be effective deposition aids is that they can form coascervates with the anionic surfactant.

Suitable cationic and nonionic polymers for use as a deposition aid herein include polyethylene glycols, polypropylene glycols, hydrolyzed silk proteins, hydrolyzed milk proteins, hydrolyzed keratin proteins, guar hydroxypropyltrimonium chloride, polyquats, silicone polymers and mixtures thereof. When cationic or nonionic polymers are employed as the deposition aid, they are utilized at levels ranging from 0.1% to 1%, preferably from 0.15% to 0.8%, more preferably from 0.2% to 0.6% by weight of the composition.

Lipophilic skin moisturizing agents are especially preferred as a deposition aid in the present invention. In addition to providing improved antibacterial efficacy compared to compositions which do not contain a lipid deposition agent, the lipid skin moisturizing agent provides a moisturizing benefit to the user of the personal cleansing product when the lipophilic skin moisturizing agent is deposited to the user's skin. When lipophilic skin moisturizing agents are used as the deposition aid herein, they are employed at a level of 1% to 30%, preferably from 3% to 25%, most preferably from 5% to 25% by weight of the composition.

Two types of rheological parameters are used to define the lipophilic skin moisturizing agent used herein. The viscosity of the lipophilic skin moisturizing agent is represented by consistency (k) and shear index (n). The lipophilic skin moisturizing agents for use herein typically have a consistency (k) ranging from 5 to 5,000 poise, preferably from 10 to 3,000 poise, more preferably from 50 to 2,000 poise, as measured by the Consistency (k) Method hereinafter set forth in the Analytical Methods section. Suitable lipophilic skin moisturizing agents for use herein further have a shear index (n) ranging from 0.01 to 0.9, preferably from 0.1 to 0.5, more preferably from 0.2 to 0.5, as measured by the Shear Index Method hereinafter set forth in the Analytical methods section.

While not being bound by any theory, it is believed that lipophilic skin moisturizing agents having rheology properties other than those defined herein are either too easily emulsified and hence will not deposit, or are too "stiff" to adhere or deposit on to skin and provide a moisturization benefit. In addition, the rheological properties of the lipophilic skin moisturizing agent are also important to user perception. Some lipophilic skin moisturizing agents, on deposition to the skin, are considered too sticky and are not preferred by the user.

In some cases, the lipophilic skin moisturizing agent can also desirably be defined in terms of its solubility parameter, as defined by Vaughan in Cosmetics and Toiletries, Vol. 103,

WO 98/55093

PCT/US98/10971

21

p. 47-69, October 1988. A lipophilic skin moisturizing agent having a Vaughan solubility Parameter (VSP) from 5 to 10, preferably from 5.5 to 9 is suitable for use in the liquid personal cleansing compositions herein.

A wide variety of lipid type materials and mixtures of materials are suitable for use as the carrier in the antimicrobial personal cleansing compositions of the present invention. Preferably, the lipophilic skin conditioning agent is selected from the group consisting of hydrocarbon oils and waxes, silicones, fatty acid derivatives, cholesterol, cholesterol derivatives, di- and tri-glycerides, vegetable oils, vegetable oil derivatives, liquid nondigestible oils such as those described in U.S. Patents 3,600,186 to Mattson; Issued August 17, 1971 and 4,005,195 and 4,005,196 to Jandacek et al; both issued January 25, 1977, all of which are herein incorporated by reference, or blends of liquid digestible or nondigestible oils with solid polyol polyesters such as those described in U.S. Patent 4,797,300 to Jandacek; issued January 10, 1989; U.S. Patents 5,306,514, 5,306,516 and 5,306,515 to Letton; all issued April 26, 1994, all of which are herein incorporated by reference, and acetoglyceride esters, alkyl esters, alkenyl esters, lanolin and its derivatives, milk tri-glycerides, wax esters, beeswax derivatives, sterols, phospholipids and mixtures thereof. Fatty acids, fatty acid soaps and water soluble polyols are specifically excluded from our definition of a lipophilic skin moisturizing agent.

Hydrocarbon oils and waxes: Some examples are petrolatum, mineral oil microcrystalline waxes, polyalkenes (e.g. hydrogenated and nonhydrogenated polybutene and polydecene), paraffins, cerasin, ozokerite, polyethylene and perhydrosqualene. Blends of petrolatum and hydrogenated and nonhydrogenated high molecular weight polybutenes wherein the ratio of petrolatum to polybutene ranges from 90:10 to 40:60 are also suitable for use as the lipid skin moisturizing agent in the compositions herein.

Silicone Oils: Some examples are dimethicone copolyol, dimethylpolysiloxane, diethylpolysiloxane, high molecular weight dimethicone, mixed C1-C30 alkyl polysiloxane, phenyl dimethicone, dimethiconol, and mixtures thereof. More preferred are non-volatile silicones selected from dimethicone, dimethiconol, mixed C1-C30 alkyl polysiloxane, and mixtures thereof. Nonlimiting examples of silicones useful herein are described in U.S. Patent No. 5,011,681, to Ciotti et al., issued April 30, 1991, which is incorporated by reference.

Di- and tri-glycerides: Some examples are castor oil, soy bean oil, derivatized soybean oils such as maleated soy bean oil, safflower oil, cotton seed oil, corn oil, walnut oil, peanut oil, olive oil, cod liver oil, almond oil, avocado oil, palm oil and sesame oil, vegetable oils and vegetable oil derivatives; coconut oil and derivatized coconut oil, cottonseed oil and derivatized cottonseed oil, jojoba oil, cocoa butter, and the like.

Acetoglyceride esters are used and an example is acetylated monoglycerides.

WO 98/55093

PCT/US98/10971

22

Lanolin and its derivatives are preferred and some examples are lanolin, lanolin oil, lanolin wax, lanolin alcohols, lanolin fatty acids, isopropyl lanolate, acetylated lanolin, acetylated lanolin alcohols, lanolin alcohol linoleate, lanolin alcohol riconoleate.

It is most preferred when at least 75% of the lipophilic skin conditioning agent is comprised of lipids selected from the group consisting: petrolatum, blends of petrolatum and high molecular weight polybutene, mineral oil, liquid nondigestible oils (e.g. liquid cottonseed sucrose octaesters) or blends of liquid digestible or nondigestible oils with solid polyol polyesters (e.g. sucrose octaesters prepared from C22 fatty acids) wherein the ratio of liquid digestible or nondigestible oil to solid polyol polyester ranges from 96:4 to 80:20, hydrogenated or nonhydrogenated polybutene, microcrystalline wax, polyalkene, paraffin, cerasin, ozokerite, polyethylene, perhydrosqualene; dimethicones, alkyl siloxane, polymethylsiloxane, methylphenylpolysiloxane and mixtures thereof. When as blend of petrolatum and other lipids is used, the ratio of petrolatum to the other selected lipids (hydrogenated or unhydrogenated polybutene or polydecene or mineral oil) is preferably from 10:1 to 1:2, more preferably from 5:1 to 1:1.

Stabilizers

When a lipophilic skin moisturizing agent is employed as the deposition aid in the liquid antimicrobial compositions herein, a stabilizer is also included at a level ranging from 0.1% to 10%, preferably from 0.1% to 8%, more preferably from 0.1% to 5% by weight of the composition.

The stabilizer is used to form a crystalline stabilizing network in the liquid cleansing composition that prevents the lipophilic skin moisturizer agent droplets from coalescing and phase splitting in the product. The network exhibits time dependent recovery of viscosity after shearing (e.g., thixotropy).

The stabilizers used herein are not surfactants. The stabilizers provide improved shelf and stress stability, but allow the liquid personal cleansing composition to separate upon lathering, and thereby provide for increased deposition of the lipophilic skin moisturizing agent onto the skin. This is particularly true when the cleansing emulsions of the present invention are used in conjunction with a polymeric diamond meshed sponge implement such as that described in Campagnoli; U.S. Patent 5,144,744; Issued September 8, 1992, herein incorporated by reference.

In one embodiment of the present invention, the stabilizer employed in the personal cleansing compositions herein comprises a crystalline, hydroxyl-containing stabilizer. This stabilizer can be a hydroxyl-containing fatty acid, fatty ester or fatty soap water-insoluble wax-like substance or the like.


The crystalline, hydroxy-containing stabilizer is selected from the group consisting of:

- (i) $\text{CH}_2 - \text{OR}_1$

WO 98/55093

PCT/US98/10971

23



wherein


 R_2 is R_1 or H

 R_3 is R_1 or H

 R_4 is C_{0-20} Alkyl


 R_5 is C_{0-20} Alkyl,

 R_6 is C_{0-20} Alkyl

 $\text{R}_4 + \text{R}_5 + \text{R}_6 = \text{C}_{10-22}$

and wherein $1 \leq x+y \leq 4$;

(ii)



wherein

 R_7 is $-\text{R}_4(\text{CHOH})_x\text{R}_5(\text{CHOH})_y\text{R}_6$

M is Na^+ , K^+ or Mg^{++} , or H; and

iii) mixtures thereof;

Some preferred hydroxyl-containing stabilizers include 12-hydroxystearic acid, 9,10-dihydroxystearic acid, tri-9,10-dihydroxystearin and tri-12-hydroxystearin (hydrogenated castor oil is mostly tri-12-hydroxystearin). Tri-12-hydroxystearin is most preferred for use in the emulsion compositions herein.

When these crystalline, hydroxyl-containing stabilizers are utilized in the personal cleansing compositions herein, they are typically present at from 0.1% to 10%, preferably from 0.1% to 8%, more preferably from 0.1% to 5% of the liquid personal cleansing compositions. The stabilizer is insoluble in water under ambient to near ambient conditions.

WO 98/55093

PCT/US98/10971

24

Alternatively, the stabilizer employed in the personal cleansing compositions herein can comprise a polymeric thickener. When polymeric thickeners as the stabilizer in the personal cleansing compositions herein, they are typically included in an amount ranging from 0.01% to 5%, preferably from 0.3% to 3%, by weight of the composition. The polymeric thickener is preferably an anionic, nonionic, cationic or hydrophobically modifier polymer selected from the group consisting of cationic polysaccharides of the cationic guar gum class with molecular weights of 1,000 to 3,000,000, anionic, cationic, and nonionic homopolymers derived from acrylic and/or methacrylic acid, anionic, cationic, and nonionic cellulose resins, cationic copolymers of dimethyldialkylammonium chloride, and acrylic acid, cationic homopolymers of dimethylalkylammonium chloride, cationic polyalkylene, and ethoxypolyalkylene imines, polyethylene glycol of molecular weight from 100,000 to 4,000,000, and mixtures thereof. Preferably, the polymer is selected from the group consisting of sodium polyacrylate, hydroxy ethyl cellulose, cetyl hydroxy ethyl cellulose, and polyquaternium 10.

Alternatively, the stabilizer employed in the personal cleansing compositions herein can comprise C10-C22 ethylene glycol fatty acid esters. C10-C22 ethylene glycol fatty acid esters can also desirably be employed in combination with the polymeric thickeners hereinbefore described. The ester is preferably a diester, more preferably a C14-C18 diester, most preferably ethylene glycol distearate. When C10-C22 ethylene glycol fatty acid esters are utilized as the stabilizer in the personal cleansing compositions herein, they are typically present at from 3% to 10%, preferably from 5% to 8%, more preferably from 6% to 8% of the personal cleansing compositions.

Another class of stabilizer which can be employed in the personal cleansing compositions of the present invention comprises dispersed amorphous silica selected from the group consisting of fumed silica and precipitated silica and mixtures thereof. As used herein the term "dispersed amorphous silica" refers to small, finely divided non-crystalline silica having a mean agglomerate particle size of less than 100 microns.

Fumed silica, which is also known as arced silica, is produced by the vapor phase hydrolysis of silicon tetrachloride in a hydrogen oxygen flame. It is believed that the combustion process creates silicone dioxide molecules which condense to form particles. The particles collide, attach and sinter together. The result of this process is a three dimensional branched chain aggregate. Once the aggregate cools below the fusion point of silica, which is 1710°C, further collisions result in mechanical entanglement of the chains to form agglomerates. precipitated silicas and silica gels are generally made in aqueous solution. See, Cabot Technical Data Pamphlet TD-100 entitled "CAB-O-SIL® Untreated Fumed Silica Properties and Functions", October 1993, and Cabot Technical Dat Pamphlet TD-104 entitled "CAB-O-SIL®

WO 98/55093

PCT/US98/10971

25

Fumed Silica in Cosmetic and Personal Care Products", March 1992, both of which are herein incorporated by reference.

The fumed silica preferably has a mean agglomerate particle size ranging from 0.1 microns to 100 microns, preferably from 1 micron to 50 microns, and more preferably from 10 microns to 30 microns. The agglomerates are composed of aggregates which have a mean particle size ranging from 0.01 microns to 15 microns, preferably from 0.05 microns to 10 microns, more preferably from 0.1 microns to 5 microns and most preferably from 0.2 microns to 0.3 microns. The silica preferably has a surface area greater than 50 sq. m./gram, more preferably greater than 130 sq. m./gram, most preferably greater than 180 sq. m./gram.

When amorphous silicas are used as the stabilizer herein, they are typically included in the emulsion compositions at levels ranging from 0.1% to 10%, preferably from 0.25% to 8%, more preferably from 0.5% to 5%.

A fourth class of stabilizer which can be employed in the personal cleansing compositions of the present invention comprises dispersed smectite clay selected from the group consisting of bentonite and hectorite and mixtures thereof. Bentonite is a colloidal aluminum clay sulfate. See Merck Index, Eleventh Edition, 1989, entry 1062, p. 164, which is incorporated by reference. Hectorite is a clay containing sodium, magnesium, lithium, silicon, oxygen, hydrogen and fluorine. See Merck Index, eleventh Edition, 1989, entry 4538, p. 729, which is herein incorporated by reference.

When smectite clay is employed as the stabilizer in the personal cleansing compositions of the present invention, it is typically included in amounts ranging from 0.1% to 10%, preferably from 0.25% to 8%, more preferably from 0.5% to 5%.

Other known stabilizers, such as fatty acids and fatty alcohols, can also be employed in the compositions herein. Palmitic acid and lauric acid are especially preferred for use herein.

F. OPTIONAL INGREDIENTS

The compositions of the present invention can comprise a wide range of optional ingredients. The CTFA International Cosmetic Ingredient Dictionary, Sixth Edition, 1995, which is incorporated by reference herein in its entirety, describes a wide variety of nonlimiting cosmetic and pharmaceutical ingredients commonly used in the skin care industry, which are suitable for use in the compositions of the present invention. Nonlimiting examples of functional classes of ingredients are described at page 537 of this reference. Examples of these functional classes include: abrasives, anti-acne agents, anticaking agents, antioxidants, binders, biological additives, bulking agents, chelating agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, emulsifiers, external analgesics, film formers, fragrance components, humectants, opacifying agents, plasticizers, preservatives, propellants, reducing agents, skin bleaching agents, skin-conditioning agents (emollient,

WO 98/55093

PCT/US98/10971

26

humectants, miscellaneous, and occlusive), skin protectants, solvents, foam boosters, hydrotropes, solubilizing agents, suspending agents (nonsurfactant), sunscreen agents, ultraviolet light absorbers, and viscosity increasing agents (aqueous and nonaqueous). Examples of other functional classes of materials useful herein that are well known to one of ordinary skill in the art include solubilizing agents, sequestrants, and keratolytics, and the like.

II. CHARACTERISTICS

The rinse-off antimicrobial cleansing compositions herein, have the following characteristics.

A. BACTERIAL EFFECTIVENESS

The rinse of antimicrobial cleansing compositions of the present invention have one of three characteristics of bacterial effectiveness.

GRAM NEGATIVE RESIDUAL EFFECTIVENESS INDEX

The rinse-off antimicrobial cleansing compositions of the present invention have a Gram Negative Residual Effectiveness Index of greater than 0.3 (50% reduction), preferably greater than 1.0 (90% reduction), more preferably greater than 1.3 (95% reduction), and most preferably greater than 1.7 (98% reduction). The Gram Negative Residual Effectiveness Index is measured by the *In-Vivo* Residual Effectiveness on *Escherichia coli* Test described hereinafter in the Analytical Methods Section. The index represents a difference in base ten logarithm values of bacterial concentrations between a test sample and a control. For example, an index of 0.3 represents a reduction in log values of 0.3 ($\Delta\log = 0.3$) which in turn represents a 50% reduction of bacteria counts.

GRAM POSITIVE RESIDUAL EFFECTIVENESS INDEX

The rinse-off antimicrobial cleansing compositions of the present invention comprise a Gram Positive Residual Effectiveness Index of greater than 1.8 (98.5% reduction), preferably greater than 2.0 (99% reduction), and more preferably greater than 2.3 (99.5% reduction). The Gram Positive Residual Effectiveness Index is measured by the *In-Vivo* Residual Effectiveness on *Staphylococcus aureus* Test described herein. The index represents a difference in base ten logarithm values of bacterial concentrations between a test sample and a control. For example, an index of 1.8 represents a reduction in log values of 1.8 ($\Delta\log = 1.8$) which in turn represents a 98.5% reduction of bacteria counts.

IMMEDIATE GERM REDUCTION INDEXES

The rinse-off antimicrobial cleansing compositions provide improved immediate germ reduction. The degree of reduction can be measured either after one-wash or after ten washes of the *In-Vivo* Health Care Personal Handwash Test described herein. When measured after one wash the rinse-off antimicrobial cleansing composition has One-wash Immediate Germ Reduction Index of greater than 2.5 (99.7% reduction), preferably greater than 2.7, more

WO 98/55093

PCT/US98/10971

27

preferably greater than 3.0 (99.9% reduction), and most preferably greater than 3.3 (99.95% reduction). The index represents a difference in base ten logarithm values of bacterial concentrations between before and after washing. For example, an index of 2.5 represents a reduction in log values of 2.5 ($\Delta \log = 2.5$) which in turn represents a 99.7% reduction of bacteria counts. When measure after ten washes the rinse-off antimicrobial cleansing composition has Ten-wash Immediate Germ Reduction Index of greater than 2.8 (99.85% reduction), preferably greater than 3.0 (99.9% reduction), more preferably greater than 3.3 (99.95% reduction), even more preferably greater than 3.7 (99.98% reduction), and most preferably greater than 4.2 (99.994% reduction).

B. MILDNESS INDEX

The rinse-off antimicrobial cleansing compositions of the present invention comprise a Mildness Index of greater than 0.3, preferably greater than 0.4, and more preferably greater than 0.6. The Mildness Index is measured by the Forearm Controlled Application Test (FCAT) described herein.

III. METHODS OF MANUFACTURE OF RINSE-OFF ANTIMICROBIAL CLEANSING COMPOSITION

The rinse-off antimicrobial personal cleansing compositions of the present invention are made via art recognized techniques for the various forms of personal cleansing products.

IV. METHODS OF USING THE RINSE-OFF ANTIMICROBIAL CLEANSING COMPOSITION

The rinse-off antimicrobial personal cleansing compositions of the present invention are useful for personal cleansing, especially for cleansing of the hands. Typically, a suitable or effective amount of the cleansing composition is applied to the area to be cleansed. Alternatively, a suitable amount of the cleansing composition can be applied via intermediate application to a washcloth, sponge, pad, cotton ball, puff or other application device. If desired, the area to be cleansed can be premoistened with water. The compositions of the present invention are combined with water during the cleansing process and rinsed-off from the skin. Generally, an effective amount of product to be used will depend upon the needs and usage habits of the individual. Typical amounts of the present compositions useful for cleansing range from 0.1 mg/cm² to 10 mg/cm², preferably from 0.3 mg/cm² to 3 mg/cm² skin area to be cleansed.

ANALYTICAL TEST METHODS

MICROTOX RESPONSE TEST

Reference: Microtox Manual: A Toxicity Testing Handbook, 1992

Volume I-IV; Microbics Corporation.

Equipment: Microtox M500 Toxicity Testing Unit; Microbics Corporation

WO 98/55093

PCT/US98/10971

28

Connected to computer for data acquisition and analysis according to above reference.

Procedure:

1. Preparation of Sample Stock Solution (Standard Concentration: 1000 ppm)

The stock solution of the test anionic surfactant sample is prepared and used as a stock solution from which all other dilutions are made. The standard "starting concentration", the highest concentration to be tested, is 500 ppm. (If a 500 ppm starting concentration fails to give a calculable result, e.g. an active surfactant kills all reagent at all dilutions, the starting concentration can be adjusted based on a known range of EC50 values of previously tested surfactants.) The stock solution is prepared at two times the starting concentration.

- a) Add 0.1g (or adjusted amount if required) of anionic surfactant, accounting for activity of raw material, to beaker.
- b) Microtox Diluent (2% NaCl, Microbics Corp.) is added to total 100g.
- c) Stir solution to make sure of adequate mixing.

2. Reconstitution of Microtox Reagent and Preparation of Assay

- a) Turn on test unit and allow reagent well temperature to equilibrate at 5.5°C and incubator block and read well temperature to equilibrate at 15°C.
- b) Place a clean cuvette (Microbics Corp.) in the reagent well, and fill with 1.0 ml of Microtox Reconstitution Solution (distilled water, Microbics, Corp.). Allow to cool for 15 minutes.
- c) Reconstitute standard vial of Microtox Acute Toxicity Reagent (*Vibrio fischeri*, Microbics Corp.) by quickly adding the 1.0 ml of the cooled reconstitution solution to the reagent vial.
- d) Swirl solution in the reagent vial for 2-3 seconds then pour reconstituted reagent back into the cooled cuvette and return the vial to the reagent well. Allow to stabilize for 15 minutes.
- e) Place 8 cuvettes containing 500 µl of Microtox Diluent, as assay, into the incubator wells of the test unit. Let cool for 15 minutes.

3. Test Substance Dilution

Prepare 7 serial dilutions of the test substance from the sample stock solution. The final volume of all cuvettes must be 1.0 ml.

- a) Place 8 empty cuvettes into a test tube rack.
- b) Add 1.0 ml of Microtox Diluent solution to tubes 1-7.
- c) Add 2.0 ml of the sample stock solution (1000 ppm) in cuvette 8.
- d) Transfer 1.0 ml solution from cuvette 8 to cuvette 7 and mix cuvette 7.

WO 98/55093

PCT/US98/10971

29

e) Serially transfer 1.0 ml from the newly formed solution to the subsequent cuvette (7 to 6, 6 to 5 etc.). Remove 1.0 ml of solution from cuvette 2 and discard. Cuvette 1 is the blank containing only Microtox Diluent. Place the cuvettes into the test unit incubation wells keeping them in order of lowest to highest concentration. These cuvettes should correspond with the 8 cuvettes prepared in step 2 above. Allow to cool for 15 minutes.

4. Assay and Sample Bioluminescence Testing

a) Add 10 µl of reconstituted reagent to the 8 precooled cuvettes of assay prepared in step 2 above (containing 500 µl of diluent). Allow 15 minutes for reagent to stabilize.

b) Start Microtox Data Capture and Reporting Software (Microbics Corp.), select START TESTING, input file name and description, correct starting concentration in ppm (500 if standard concentration is used) and number of controls (1) and dilutions (7). Time 1 should be selected as 5 minutes, time 2 is NONE. Press enter then the space bar to begin testing.

c) Place the assay cuvette containing reagent which corresponds to the test blank into the read well and press SET. After the cuvette has resurfaced press READ and the value will be captured by the computer.

d) Similarly read the remaining 7 cuvettes containing reagent when prompted by the computer by pressing the READ button with the correct cuvette in the READ well.

e) After all 8 initial readings have been taken, transfer 500 µl of the diluted test substance into their corresponding cuvette containing the reagent. Mix by vortexing or swirling and return to the incubation wells. The computer will count for five minutes and prompt you to begin final readings.

f) Take final readings by placing the correct cuvette containing reagent and diluted test surfactant into the read well and pressing READ when prompted by the computer.

5. Data Analysis

The concentration of test substance, in ppm, that decreases the bioluminescence of the Microtox Acute Toxicity Reagent by 50% from the starting value (EC50 Value) can be calculated using the *Run Statistics on Data File* option of the Microtox Software (recommended) or by conducting a linear regression of the data (% reduction vs. log of concentration). % Reductions are calculated using the following formulas:

$$\frac{\text{Final Reading of Reagent Blank}}{\text{Initial Reading of Reagent Blank}} = \text{Correction Factor}$$

$$\frac{\text{Final Reading of Reagent with Diluted Test Substance}}{\text{Initial Reading of Reagent with Diluted Test Substance}} = \text{Reduction Factor}_x$$

WO 98/55093

PCT/US98/10971

30

where x means at a corresponding concentration

$$\% \text{ Reduction} = \frac{\text{Correction Factor}_x - \text{Reduction Factor}}{\text{Correction Factor}}$$

The Microtox Index is the EC50 value in ppm.

SOLUBILITY SLOPE, K

Equipment: Liquid Scintillation Counter equipped with correct quench curve for liquid scintillation fluid used (Ultima Gold, Packard Instrument Co.)

1. Preparation of ^{14}C labeled Triclosan®
 - a) Add 5.00 g of regular triclosan (TCS) powder to a 20 ml vial.
 - b) Add 10 μCi of ^{14}C TCS and 1 ml of acetone.
 - c) Stir the solution for 3 minutes or until all TCS is dissolved.
 - d) Blow in N_2 to remove most solvent until it solidifies again.
 - e) Grind the solid to powder and dry it under N_2 overnight to yield the labeled material ready for use.
 - f) Measure activity of TCS in DPM/g to use as conversion factor for later samples.
 1. Place 0.1g of powdered TCS (note weight) from step e above into liquid scintillation vial.
 2. Add 10 ml of liquid scintillation fluid (Ultima Gold).
 3. Place in liquid scintillation counter and count decays per minute (DPM) of sample.
 4. Divide DPM by TCS weight from step 1-f-1 to determine conversion factor (DPM/g TCS).
2. Solubility protocol
 - a) Prepare stock solution of TCS deprived formula with anionic surfactant level of 16% in 7-9 grain tap water..
 - b) Place 8 empty cuvettes into a test tube rack.
 - c) Add 3 ml of the stock solution into a scintillation vial 1.
 - d) Prepare five individual 3 ml solutions which are 1:2, 1:4, 1:8, 1:16, and 1:32 dilutions of the stock solution in five scintillation vials (ending concentrations are 8%, 4%, 2%, 1%, and 0.5%).
 - e) To each vial add 0.05g of the radio labeled TCS (from step 1-e above) and a magnetic stirring bar. Stir the vials as a group for at least 2 hours. If the TCS solid phase disappears, add additional TCS to ensure phase equilibrium.

WO 98/55093

PCT/US98/10971

31

- f) For each dilution, remove 1.0 ml, place in 1.5 ml microcentrifuge tube, and centrifuge it for 5 minutes at 1500 RPM.
- g) Remove 0.1 -0.4 g (note weight) from top layer of centrifuged sample and place in a clean liquid scintillation vial.
- h) Add 10 ml of liquid scintillation cocktail (Ultima Gold) to the vial.
- i) Count the vial's DPM using the liquid scintillation counter.
- j) Covert DPM to TCS weight using conversion factor from step 1-f above.
- k) Calculate percentage TCS (maximum solubility in sample) by dividing by weight from step 2-g.
- l) Repeat g through l for each serial dilution of anionic surfactant.

3. Calculation of K

The Solubility Slope, K, is calculated by conducting a linear regression of maximum TCS solubility vs. surfactant concentration within the limits discussed below.

- a) For almost all surfactants the slope of the solubility curve between 1 and 2% surfactant is representative of K.
- b) For some surfactants the maximum TCS solubility curve remains linear outside the 1-2% surfactant region. K must then be calculated from this entire linear region, such as from 0-4%, 1-4%, or 0.5-2% surfactant levels.

It is important that K is calculated near the 2% surfactant range because this is an approximate concentration of surfactant in a diluted cleansing composition.

IN VIVO RESIDUAL EFFECTIVENESS ON *Escherichia coli*

References: Aly, R; Maibach, H.I.; Aust, L.B.; Corbin, N.C.; Finkey, M.B. 1994.

- 1. *In vivo effect of antimicrobial soap bars containing 1.5% and 0.8% trichlorocarbanilide against two strains of pathogenic bacteria.* J. Soc. Cosmet. Chem., 35, 351-355, 1981.
- 2. *In vivo methods for testing topical antimicrobial agents.* J. Soc. Cosmet. Chem., 32, 317-323.

1. Test Design

Residual Antibacterial efficacy of liquid and bar soap antimicrobial products are quantified in the following method. Reductions are reported from a control, non-antibacterial placebo soap, without further treatment, used on one of the subjects forearms. By definition the antibacterial placebo will show no residual effectiveness in the test.

2. Pre-Test Phase

WO 98/55093

PCT/US98/10971

32

Subjects are instructed not to use antibacterial products for 7 days prior to testing. Immediately before test, the subjects hands are examined for cuts/broken skin that would preclude them from participating.

3. Wash Procedure

- a) Wash both forearms with control soap one time to remove any contaminants or transient bacteria. Rinse and dry forearms
- b) Test monitor wets gloved hands, places 1.0 ml of liquid test product (bar treatments are done according to above references) on forearm of subject, and lathers entire volar forearm with hand for 45 sec.
- c) Subjects forearms are then rinsed with 90-100°F tap water at a rate of 1 GPM for 15 seconds.
- d) Steps b-c are repeated two times (total 3 washes) for the test product.
- e) Arm is patted dry with paper towel and test sites are marked (~8.6 cm² circle with rubber stamp).
- f) This entire procedure (a - e) is repeated on other forearm of subject with control product.

4. Inoculation Procedure

- a) *E. coli* inoculum (ATCC 10536, grown from lyophilized stock in Soybean-casein broth at 37C for 18-24 hrs) is adjusted to approximately 10⁸ organisms/ml (0.45 transmittance vs. TSB blank on specrophotometer).
- b) Each test site is inoculated with 10 µl of *E. coli*. Inoculum is spread with inoculating loop into a ~3 cm² circle and covered with a Hilltop Chamber (Hilltop Research Inc.).
- c) This procedure is repeated for each test site on each forearm.

5. Sampling Bacteria (Extraction Procedure)

- a) Prepare sampling solution of 0.04% KH₂PO₄, 1.01% Na₂HPO₄, 0.1% Triton X-100, 1.5% Polysorbate 80, 0.3% Lecithin in water, adjusted to pH 7.8 with 1 N HCl.
- b) Exactly 60 minutes after inoculation, the Hilltop Chamber is removed from the site from which a sample is to be taken. A 8.6 cm² sampling cup is placed over the site.
- c) 5 ml of sampling solution is added to the cup.
- d) Extract the bacteria by gently rubbing site with glass police man for 30 seconds.
- e) Remove sampling solution with pipette and place in a sterile labeled test tube.
- f) Repeat extraction with 5 ml of sampling fluid. This entire extraction procedure is repeated for each site 60 minutes after inoculation.

6. Quantifying Bacteria

WO 98/55093

PCT/US98/10971

33

- a) Prepare phosphate buffer solution of 0.117% Na_2HPO_4 , 0.022% NaH_2PO_4 , and 0.85% NaCl adjusted to pH 7.2-7.4 with 1 N HCl .
- b) 1.1 ml of the sampling solution is aseptically removed from the tube, 0.1 ml of the solution is spread plated onto trypticase-soy agar containing 1.5% Polysorbate 80 . Remaining 1 ml is placed into 9 ml of sterile phosphate buffer achieving a 1:10 dilution of the sampling solution. This process is repeated 3 more times (each serial dilution).
- c) The plates are inverted and incubated for 24 hours at 35C.
- d) Colonies formed on plates are then enumerated and results are calculated by multiplying the counts by the dilution factor (original sample = 10, first dilution = 100, second dilution = 1000, etc.) and the final results are reported as the number of colony forming units per ml (CFU's/ml).

7. Index Calculation

Gram Negative Residual Efficacy Index =

$$\log_{10} (\text{CFU's/ml of placebo site}) - \log_{10} (\text{CFU's/ml of test product site})$$

IN VIVO RESIDUAL EFFECTIVENESS ON *Staphylococcus aureus*

References: Aly, R; Maibach, H.I.; Aust, L.B.; Corbin, N.C.; Finkey, M.B. 1994.

1. *In vivo effect of antimicrobial soap bars containing 1.5% and 0.8% trichlorocarbanilide against two strains of pathogenic bacteria.* J. Soc. Cosmet. Chem., 35, 351-355, 1981.
2. *In vivo methods for testing topical antimicrobial agents.* J. Soc. Cosmet. Chem., 32, 317-323.

1. Test Design

Residual Antibacterial efficacy of liquid and bar soap antimicrobial products are quantified in the following method. Reductions are reported from a control, non-antibacterial placebo soap, without further treatment, used on one of the subjects forearms. By definition the antibacterial placebo will show no residual effectiveness in the test.

2. Pre-Test Phase

Subjects are instructed not to use antibacterial products for 7 days prior to testing. Immediately before test, the subjects hands are examined for cuts/broken skin that would preclude them from participating.

3. Wash Procedure

- a) Wash both forearms with placebo soap one time to remove any contaminants or transient bacteria. Rinse and dry forearms

WO 98/55093

PCT/US98/10971

34

- b) Test monitor wets gloved hands, places 1.0 ml of liquid test product (bar treatments are done according to above references) on forearm of subject, and lathers entire volar forearm with hand for 45 sec.
- c) Subjects forearms are then rinsed with 90-100°F tap water at a rate of 1 GPM for 15 seconds.
- d) Steps b-c are repeated two times (total 3 washes) for the test product.
- e) Arm is patted dry with paper towel and test sites are marked (~8.6 cm² circle with rubber stamp).
- f) This entire procedure (a-e) is repeated on other forearm of subject with control product.

4. Inoculation Procedure

- a) *S. aureus* inoculum (ATCC 27217, grown from lyophilized stock in Soybean-casein broth at 37C for 18-24 hrs) is adjusted to approximately 10⁸ organisms/ml (0.45 transmittance vs. TSB blank on specrophotometer).
- b) Each test site is inoculated with 10 µl of *S. aureus*. Inoculum is spread with inoculating loop into a ~3 cm² circle and covered with a Hilltop Chamber (Hilltop Research Inc.).
- c) This procedure is repeated for each test site on each forearm.

5. Sampling Bacteria (Extraction Procedure)

- a) Prepare sampling solution of 0.04% KH₂PO₄, 1.01% Na₂HPO₄, 0.1% Triton X-100, 1.5% Polysorbate 80, 0.3% Lecithin in water, adjusted to pH 7.8 with 1 N HCl.
- b) Exactly 60 minutes after inoculation, the Hilltop Chamber is removed from the site from which a sample is to be taken. A 8.6 cm² sampling cup is placed over the site.
- c) 5 ml of sampling solution is added to the cup.
- d) Extract the bacteria by gently rubbing site with glass police man for 30 seconds.
- e) Remove sampling solution with pipette and place in a sterile labeled test tube.
- f) Repeat extraction with 5 ml of sampling fluid. This entire extraction procedure is repeated for each site 60 minutes after inoculation.

6. Quantifying Bacteria

- a) Prepare phosphate buffer solution of 0.117% Na₂HPO₄, 0.022% NaH₂PO₄, and 0.85% NaCl adjusted to pH 7.2-7.4 with 1 N HCl.
- b) 1.1 ml of the sampling solution is aseptically removed from the tube, 0.1 ml of the solution is spread plated onto trypticase-soy agar containing 1.5% Polysorbate 80. Remaining 1 ml is placed into 9 ml of sterile phosphate buffer achieving a 1:10 dilution of the sampling solution. This process is repeated 3 more times (each serial dilution).
- c) The plates are inverted and incubated for 24 hours at 35C.

WO 98/55093

PCT/US98/10971

35

d) Colonies formed on plates are then enumerated and results are calculated by multiplying the counts by the dilution factor (original sample = 10, first dilution = 100, second dilution = 1000, etc.) and the final results are reported as the number of colony forming units per ml (CFU's/ml).

7. Index Calculation

Gram Positive Residual Efficacy Index =

$$\log_{10} (\text{CFU's/ml of placebo site}) - \log_{10} (\text{CFU's/ml of test product site})$$

IN-VIVO HEALTH CARE PERSONAL HANDWASH TEST (HCPHWT)

Reference: Annual Book of ASTM Standards, Vol. 11.05; ASTM Designation: E 1174 - 94;

"Standard Test Method for Evaluation of Health Care Personnel Handwash Formulation"

1. The test method used is identical to the method explained in this reference with the following changes/clarifications.

a. Testing on a subject was finished after the one wash extraction, when only one-wash data was desired. The test requires at least four subjects to be valid.

b. Historical Data was used as a control in this protocol. (i.e. a control soap was not run in every test)

c. Test Materials

Organism: *Serratia marcescens* ATCC 14756 (incubated 18-24 hrs. at 25C in soybean casein broth, adjusted to $\sim 10^8$ organisms/ml by diluting to 0.45 transmittance with a spectrophotometer)

Dilution Fluid: phosphate buffer (0.1% Triton X-100, 00.3% Lecithin, 1.5% Tween 80) adjusted to pH 7.2 with 1 N HCl

Agar: Soybean casein agar with 1.5% polysorbate 80

Wash and Rinse Procedure: 2.0 ml of product was used for the handwashes.

d. Bacteria were enumerated by performing serial dilutions (1:10) of inoculum or extracted samples and spreading 0.1 ml of dilution on plates. Results are reported as the log reduction of bacteria from baseline.

One - wash Immediate Germ Reduction Index= Log (CFU's) in Baseline Extraction- Log (CFU's) in Post - One Wash Extraction

Ten - wash Immediate Germ Reduction Index= Log (CFU's) in Baseline Extraction- Log (CFU's) in Post - Ten Wash Extraction

e. Hands were decontaminated by submersion in 70% ethanol for 15 sec. and then a five minute wash with control soap and water.

FOREARM CONTROLLED APPLICATION TEST (FCAT)

WO 98/55093

PCT/US98/10971

36

Reference: Ertel, K. D., et al.; "A Forearm Controlled Application Technique for Estimating the Relative Mildness of Personal Cleansing Products"; J. Soc. Cosmet. Chem. 46 (1995) 67-76

The Forearm Controlled Application Test, or FCAT, is a comparative test which discriminates differences in product mildness to the skin. A test product is compared to a standard soap based cleansing bar control.

Test Group Restrictions

Test groups of 20-30 subjects, 18 to 55 years of age, who regularly wash with soap are used. Potential subjects who (1) have an initial dryness grade of 3.0 or higher on the forearms as assessed during the initial examination, (2) have skin cancer, eczema, or psoriasis on the forearms, (3) are receiving injectable insulin, (4) are pregnant or lactating, or (5) are receiving treatment for skin problems or contact allergy are excluded. Subjects are to avoid hot tubs, swimming, and sun lamps, and to refrain from applying any soaps, cleansing products, creams, or gels to their forearms for the duration of the study. Subjects are to keep water off their forearms for at least two hours before the grading process. The studies are executed using a blinded, random product order format. Clinical assistant should verify the correct treatment sequence and document such before washing each subject.

Products are applied to the forearms a total of nine (9) times: two (2) times each day on the first four (4) days of the study and one (1) time on the final day. Visits to the test facility for washing must be spaced by a minimum of three (3) hours.

All clinical assistants must wear disposable gloves during wash procedure, rinsing them between treatments, and changing between subjects.

Control Product

The control product is a rolled bar soap containing:

56.1%	Sodium Tallowate
18.7%	Sodium Cocoate
0.7%	Sodium Chloride
24%	Water
0.5%	Minors (Perfume, Impurities)

Product Application Procedure

Both test and control products are tested on the same arm. The following test procedure is used.

1. The subject wets the entire surface of his/her volar forearm with 95-100°F tap water by holding the arm briefly under running tap water.

WO 98/55093

PCT/US98/10971

37

2. A clinical assistant wets one-quarter sheet (approximately 8" x 6") of Masslinn® towel with tap water, then squeezes the towel gently to remove excess water.
3. A clinical assistant applies the products to the arm, beginning with the product designated for the site nearest the elbow, using the appropriate procedure as follows:

Liquid Product

- a. Dispense 0.10 cc of test product from a syringe into the center of the appropriate marked area.
- b. Wet two fingers of gloved (latex) hand under the running tap (index and middle fingers).
- c. Move wetted fingers in a circular motion over the application site for 10 seconds to lather product.
- d. Lather remains on the application site for 90 seconds, then is rinsed off with running tap water for 15 seconds, taking care not to wash lather off the adjacent sites. After 10 seconds of the rinse has expired, the Clinical Assistant will gently rub the site being rinsed with her two gloved fingers for the remaining 5 seconds of the rinse..

Bar Product

- a. Wet two fingers of gloved (latex) hand under the running tap (index and middle fingers).
- b. Wet bar by holding bar briefly under running tap water. Test bars must be wet under a running tap at the start of each day.
- c. Rub wetted fingers in a circular motion, over the surface of the bar, for 15 seconds to form lather on bar and fingers.
- d. Rub the lathered fingers on the application site in a circular motion for 10 seconds to lather product on the skin.
- e. Lather remains on the application site for 90 seconds, then is rinsed off with running tap water for 15 seconds, taking care not to wash lather off the adjacent sites. After 10 seconds of the rinse has expired, the Clinical Assistant will gently rub the site being rinsed with her two gloved fingers for the remaining 5 seconds of the rinse..

Wipe Products

- a. Fold wipe in half, crosswise, and gently rub the wipe in a curricular motion within the appropriate area.
- b. Allow site to air dry for 90 seconds. Do not rinse site.

Leave-on Product

- a. Dispense 0.10 cc of test product from a syringe into the center of the appropriate marked area.
- b. Move gloved fingers in a circular motion over the application site for 10 seconds.

WO 98/55093

PCT/US98/10971

38

- c. Allow site to air dry for 90 seconds. Do not rinse site.
4. While waiting for the 90 second residence time to expire, the above procedure will be repeated on the remaining application site on that arm, working down the arm toward the wrist.
5. Steps 1-4 are repeated on the appropriate test areas so two applications of product are made to test areas.
6. After all of the application areas have two applications of products, the clinical assistant gently pats the subject's arm dry with a disposable paper towel.

Evaluation

The skin on each treatment area is evaluated by an expert grader at baseline and three hours after the final study wash. The treatment areas are evaluated under 2.75x magnification (model KFM-1A Luxo Illuminated Magnifying Lamp, Marshall Industries, Dayton, OH) with controlled lighting (General Electric Cool White, 22-watt, 8" Circuline fluorescent bulb).

The skin is evaluated by an expert grader, for dryness and a rating is assigned based on the definitions set forth below.

Table 1
Forearm Grading Scale

Rating	Skin Dryness
0	No dryness
1.0	Patches of slight powderiness and occasional patches of small scales may be seen.
2.0	Generalized slight powderiness. Early cracking or occasional small lifting scales may be present.
3.0	Generalized moderate powderiness and/or heavy cracking and lifting scales.
4.0	Generalized heavy powderiness and/or heavy cracking and lifting scales.
5.0	Generalized high cracking and lifting scales. Eczematous change may be present. Powderiness may be present but not prominent. May see bleeding crack.
6.0	Generalized severe cracking. Eczematous change may be present. Bleeding cracks may be present. Scales large, may be beginning to disappear.

The FCAT generally produces only mild to moderate skin irritation; however, if a treated site reaches a rating of 5.0 or greater, at any time during the study, treatment of all sites on that subject should be discontinued.

Data

After all subjects have been evaluated at the end of the test, the following values are determined:

R_{c0} = The average rating of control product area at baseline

WO 98/55093

PCT/US98/10971

39

R_{cf} = The average rating of control product area at test end

R_{t_0} = The average rating of test product area at baseline

R_{tf} = The average rating of test product area at test end.

There are many external conditions which could influence the FCAT, such as relative humidity and water softness. The test is valid only if sufficient response is observed in the skin to the control product. The control response must be greater than 1.0 (i.e., $R_{cf} - R_{c_0} \geq 1.0$) for the test to be valid.

Given a valid test, the Mildness Index of the test product is the difference in the skin responses to two products.

$$\text{Mildness Index} = (R_{cf} - R_{c_0}) - (R_{tf} - R_{t_0})$$

CONSISTENCY (k) AND SHEAR INDEX (n) OF THE LIPOPHILIC SKIN MOISTURIZING AGENT

The Carrimed CSL 100 Controlled Stress Rheometer is used to determine Shear Index, n, and Consistency, k, of the lipophilic skin moisturizing agent used herein. The determination is performed at 35°C with the 4 cm 2° cone measuring system typically set with a 51 micron gap and is performed via the programmed application of a shear stress (typically from 0.06 dynes/sq. cm to 5,000 dynes/sq. cm) over time. If this stress results in a deformation of the sample, i.e. strain of the measuring geometry of at least 10-4 rad/sec, then this rate of strain is reported as a shear rate. These data are used to create a viscosity μ Vs. shear rate $\dot{\gamma}$ flow curve for the material. This flow curve can then be modeled in order to provide a mathematical expression that describes the material's behavior within specific limits of shear stress and shear rate. These results were fitted with the following well accepted power law model (see for instance: Chemical Engineering, by Coulson and Richardson, Pergamon, 1982 or Transport Phenomena by Bird, Stewart and Lightfoot, Wiley, 1960):

$$\text{Viscosity, } \mu = k (\dot{\gamma})^{n-1}$$

VISCOSITY OF THE RINSE-OFF ANTIMICROBIAL CLEANSING COMPOSITION

The Wells-Brookfield Cone/Plate Model DV-II+ Viscometer is used to determine the viscosity of the rinse-off antimicrobial cleansing compositions herein. The determination is performed at 25°C with the 2.4 cm° cone (Spindle CP-41) measuring system with a gap of 0.013 mm between the two small pins on the respective cone and plate. The measurement is performed by injecting 0.5 ml of the sample to be analyzed between the cone and plate and rotating the cone at a set speed of 1 rpm. The resistance to the rotation of the cone produces a torque that is proportional to the shear stress of the liquid sample. The amount of torque is read and computed by the viscometer into absolute centipoise units (mPa's) based on geometric constants of the cone, the rate of rotation, and the stress related torque.

WO 98/55093

PCT/US98/10971

40

EXAMPLES

The following examples further describe and demonstrate embodiments within the scope of the present invention. In the following examples, all ingredients are listed at an active level. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention, as many variations thereof are possible without departing from the spirit and scope of the invention.

Ingredients are identified by chemical or CTFA name.

Liquid Handsoap Component	Weight %								
	1	2	3	4	5	6	7	8	9
Ammonium Lauryl Sulfate	0.00	2.60	5.00	0.00	6.60	3.2	2.9	0.00	3.1
Sodium Lauryl Sulfate	3.50	0.00	0.00	0.00	0.00	0.00	0.00	3.50	0.00
Ammonium Laureth-3 Sulfate	0.00	7.90	0.00	5.20	5.20	9.5	5.5	0.00	6.6
Sodium Laureth-3 Sulfate	7.00	0.00	0.00	0.00	0.00	0.00	0.00	7.00	0.00
C ₁₄ -C ₁₆ Sodium Alpha Olefin Sulfonate	0.00	0.00	0.00	7.40	0.00	0.00	0.00	0.00	0.00
Sodium Myristyl Sulfate	0.00	0.00	5.00	0.00	0.00	0.00	0.00	0.00	0.00
Cocamidopropyl Betaine	0.00	0.00	0.00	1.30	0.00	0.00	0.00	0.00	0.00
Sodium Lauroamphoacetate	5.25	5.25	3.00	0.00	0.00	0.00	0.00	5.25	5.00
Citric Acid Anhydrous	0.00	6.00	0.00	0.00	0.00	6.30	6.30	0.00	0.00
Lactic Acid	0.00	0.00	0.00	5.00	0.00	0.00	0.00	0.00	0.00
Succinic Acid	8.00	0.00	4.70	0.00	0.00	0.00	0.00	0.00	0.00
Salicylic Acid	0.00	0.00	0.00	0.00	2.00	0.00	0.00	0.00	0.00
polyacrylate*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.00	8.00
Sodium Citrate	0.00	to pH 3.7	0.00	0.00	0.00	to pH 3.9	to pH 3.9	to pH 4.0	0.00
Petrolatum	0.00	0.00	0.00	0.00	0.00	16.5	12.0	0.00	12.0
Tri-hydroxystearin	0.00	0.00	0.00	0.00	0.00	0.15	0.15	0.00	0.25
Lauric Acid	0.00	0.00	0.00	0.00	0.00	1.00	1.5	0.00	1.5
Polyquaternium 10	0.40	0.40	0.15	0.30	0.20	0.60	0.10	0.40	0.1
Sodium Hydroxide	to pH 4.0	0.00	to pH 4.0	to pH 3.5	to pH 5.0	0.00	0.00	to pH 4.0	to pH 4.0
Para-chloro-meta-xyleneol	1.50	0.00	0.00	0.00	0.00	0.00	0.00	1.50	0.00
Triclosan®	0.00	0.50	1.00	0.50	0.20	0.60	0.50	0.00	0.5
Perfume	1.0	1.0	0.00	1.0	1.0	1.0	1.0	1.0	0.4
Water	Q.S.	Q.S.	Q.S.	Q.S.	Q.S.	Q.S.	Q.S.	Q.S.	Q.S.
K Value of Anionic Surfactant	< 0.40	< 0.40	< 0.21	< 0.25	< 0.40	< 0.40	< 0.40	< 0.40	< 0.40
Microtox of Anionic Surfactant	1 / 150	1 / 150	1 / 150	150 / 20	1 / 150	1 / 150	1 / 150	1 / 150	1 / 150
Head Group Size of Anionic Surfactant	Small / Large	Small / Large	Small	Small	Small / Large	Small / Large	Small / Large	Small / Large	Small / Large

WO 98/55093

PCT/US98/10971

41

Primary Chain Length of Anionic Surfactant	12	12	12-14	12-16	12	12	12	12	12
Biological Activity (Z) of acid	1.8	1.3	1.8	1.6	2.7	1.6	1.6	1.8	--

* The polyacrylate is K7058 sold by B.F. Goodrich

The liquid handsoaps shown all have a Gram Positive Residual Effectiveness Index of greater than 1.8, a Gram Negative Residual Effectiveness Index of greater than 0.3, a One-wash Immediate Germ Reduction Index of greater than 2.5, a Ten-wash Immediate Germ Reduction Index of greater than 2.8; and a Mildness Index of greater than 0.3.

Procedure for Making Liquid Handsoap Examples

1) Examples 1-5 & 8

Add all but 5 weight percent water to mix tank. Add surfactants to mix tank. Heat materials to 155°F ±10°F and mix until dissolved. Cool to less than 100°F, add acid and antibacterial active and perfumes. Mix until materials are dissolved. Adjust pH to target with required buffer (NaOH or sodium salt of acid). Add remaining water to complete product.

2. Examples 6, 7 & 9

Add all ingredients except petrolatum, active and perfume together and heat to the point necessary to melt the stabilizer (approximately 190°F for trihydroxystearin). Cool to below 115°F and add active, petrolatum and perfume. Adjust final pH using NaOH or buffer salt. Add remaining water to complete product.

Shower Gel Component	Weight %					
	1	2	3	4	5	6
Sodium or Ammonium Lauryl Sulfate	6.30	5.00	0.00	3.50	3.15	3.15
Sodium or Ammonium Laureth-3 Sulfate	4.20	15.00	5.80	7.00	9.45	9.45
Sodium or Ammonium Lauroamphoacetate	5.25	0.00	0.00	5.25	5.40	5.40
Cocoamide MEA	2.80	0.00	0.00	2.80	0.00	0.00
Cocamidopropyl Betaine	0.00	0.00	5.20	0.00	0.00	0.00
Citric Acid	6.50	0.00	0.00	8.00	6.50	6.50
Succinic Acid	0.00	0.00	2.00	0.00	0.00	0.00
Salicylic Acid	0.00	2.00	2.00	0.00	0.00	0.00
Triclocarban®	0.00	0.15	0.00	0.00	0.00	0.00
Triclosan®	1.00	0.25	0.00	0.60	0.60	0.80
Thymol Oil	0.00	0.00	2.00	0.00	1.00	0.00
Sodium Hydroxide	0.00	to pH 6	to pH 5	to pH 3.7	0.00	0.00
Sodium Citrate	to pH 4	0.00	0.00	0.00	to pH 3.5	to pH 3.9
Soybean Oil	8.00	0.00	0.00	0.00	0.00	0.00
Petrolatum	0.00	0.00	0.00	0.00	16.50	16.5
Dimethicone Emulsion	0.00	0.00	0.00	0.00	0.00	1.00
Tri-hydroxystearin	0.00	0.00	0.00	0.00	1.00	1.00
Lauric Acid	0.00	0.00	0.00	0.00	1.00	1.00

WO 98/55093

PCT/US98/10971

42

Palmitic Acid	2.20	0.00	0.00	0.00	0.00	0.00
Polyquaternium 10	0.30	0.30	0.00	0.30	0.30	0.3
Miscellaneous	8.28	2.41	1.68	1.75	1.61	1.98
Water	Q.S.	Q.S.	Q.S.	Q.S.	Q.S.	Q.S.
K Value of Anionic Surfactant	< 0.40	0.32	< 0.50	< 0.40	< 0.40	< 0.40
Microtox of Anionic Surfactant	1 / 150	1 / 150	150	1 / 150	1 / 150	1 / 150
Head Group Size of Anionic Surfactant	Small / Large	Small / Large	Large	Small / Large	Small / Large	Small / Large
Primary Chain Length of Anionic Surfactant	12	12	12	12	12	12
Biological Activity (Z) of acid	1.3	2.7	1.8 / 2.7	1.3	1.3	1.3

The shower gels shown all have a Gram Positive Residual Effectiveness Index of greater than 1.8; and a Mildness Index of greater than 0.3.

Procedure for Making Shower Gels

1) Examples 1-4

Add moisturizing oils and co-surfactants together and heat ingredients to 130-140°F until dissolved (step can be skipped for products not containing oils). In another container add primary surfactants, acid, buffer salt, preservatives, viscosity builder (salt), and polymer. Heat to 130-140°F until dissolved. Combine two mixtures (or use single mixture if no oils are present) when both are 130-140°F, then begin cooling. When mixture is below 115°F, add, antibacterial active and perfume. Adjust final pH using NaOH or remaining buffer salt. Add remaining water to complete product.

2) Examples 5 and 6

Add all ingredients except petrolatum, active and perfume together and heat to the point necessary to melt the stabilizer (approximately 190°F for trihydroxystearin). Cool to below 115°F and add active, petrolatum and perfume. Adjust final pH using NaOH or buffer salt. Add remaining water to complete product.

Bar Component	Wt%
Dextrin	58.5
Ammonium Laureth-3 Sulfate	9.00
Ammonium Lauryl Sulfate	7.00
Lactic acid	6.50
Sodium Hydroxide	to pH 3.7
Triclosan®	1.00
Titanium Dioxide	0.30
Urea	6.00
Sorbitol	0.30
Sodium Chloride	3.20
Perfume	1.00
Water	Q.S.
K Value of Anionic Surfactant	< 0.40
Microtox of Anionic Surfactant	1 / 150

WO 98/55093

PCT/US98/10971

43

Head Group Size of Anionic Surfactant	Small / Large
Primary Chain Length of anionic Surfactant	12
Microtox of Anionic Surfactant	1 / 150
Biological Activity (Z) of acid	1.45

The bar shown has a Gram Positive Residual Effectiveness Index of greater than 1.8, a Gram Negative Residual Effectiveness Index of greater than 0.3, a One-wash Immediate Germ Reduction Index of greater than 2.5, a Ten-wash Immediate Germ Reduction Index of greater than 2.8; and a Mildness Index of greater than 0.3.

Procedure for Making Bar Example

The ingredients can be processed to form bars using conventional soap line equipment. For example, processing can be carried out as follows: First add the anionic surfactants to the crutcher. Next add the acid, and incorporate enough water such that the crutcher mixture is smooth fluid and has a manageable viscosity under agitation. Adjust the pH to target with required base (NaOH). Adjust the temperature of the mixture to 160-200° F range. Next, introduce the dextrin into the mixture. Apply crutcher agitation and heat to again achieve a uniform composition at the above stated temperature range.

Pump the resulting mixture and spread it onto a conventional chill roll where the composition solidifies. Chip it off into a flake form. Convey the chips to an amalgamator where perfume and heat sensitive actives or components may be incorporated. Process the amalgamated flakes through a mill and plodder where they are extruded. Stamp into the desired bar shape.

Hair Shampoo Component	Wt%
Ammonium Lauryl Sulfate	7.00
Ammonium Laureth-3 Sulfate	9.00
Sodium Lauroamphoacetate	5.00
Malic Acid	2.00
Salicylic Acid	2.00
Sodium Hydroxide	to pH 5.0
Pyrithione Zinc	1.00
Polyquaternium 10	0.50
Perfume	1.00
Dye	0.01
Water	Q.S.
K Value of Anionic Surfactant	< 0.40
Microtox of Anionic Surfactant	1 / 150
Head Group Size of Anionic Surfactant	Small / Large
Primary Chain Length of Anionic Surfactant	12
Biological Activity (Z) of acid	1.2, 2.7

WO 98/55093

PCT/US98/10971

44

The dandruff shampoo has a Gram Positive Residual Effectiveness Index of greater than 1.8, a Gram Negative Residual Effectiveness Index of greater than 0.3, a One-wash Immediate Germ Reduction Index of greater than 2.5, a Ten-wash Immediate Germ Reduction Index of greater than 2.8; and a Mildness Index of greater than 0.3.

Procedure for Making Shampoo Examples

Add all but 5 weight percent water to mix tank. Add surfactants to mix tank. Heat materials to 155°F ±10°F and mix until dissolved. Cool to less than 100°F, add acid, antibacterial active, perfumes and dyes. Mix until materials are dissolved. Adjust pH to target with required buffer (sodium salt of acid). Add remaining water to complete product.

Liquid Laundry Detergent Component	Wt. %	Liquid Dish Detergent Component	Wt. %
C ₁₃ -C ₁₇ Sodium Paraffin Sulfonate	10.00	C ₁₃ -C ₁₇ Sodium Paraffin Sulfonate	10.00
Laureth-8	5.00	Sodium Laureth-3 Sulfate	5.00
Sodium	5.00	Cocoamidopropylhydroysultaine	5.00
Lauroamphodipropionate		Polyquaternium-10	0.30
Enzyme	1.00	Malic Acid	6.00
Ethanol	4.00	Sodium Hydroxide	to pH 4.5
Propylene Glycol	6.00	Para-chloro-meta-xyleneol	1.50
Polyquaternium-10	0.50	Perfume	1.00
Citric Acid	6.00	Water	Q.S.
Triethanolamine	to pH 4.0		
Triclosan®	1.00	K Value of Anionic Surfactant	< 0.15
Perfume	1.00	Microtox of Anionic Surfactant	n/a / 150
Water	Q.S.	Head Group Size of Anionic Surfactant	Small / Large
		Primary Chain Length of Anionic Surfactant	13-17 / 12
K Value of Anionic Surfactant	0.10	Biological Activity (Z) of acid	1.19
Microtox of Anionic Surfactant	n/a		
Head Group Size of Anionic Surfactant	Small		
Primary Chain Length of Anionic Surfactant	13-17		
Biological Activity (Z) of acid	1.3		

Hard Surface Cleaner Component	Wt. %
C ₁₄ /C ₁₆ Sodium Alpha Olefin Sulfonate	4.00
Acetic Acid	4.00
Ammonium Hydroxide	to pH 3.0
o-phenylphenol	0.25
Perfume	1.00
Water	Q.S.
K Value of Anionic Surfactant	0.23
Microtox of Anionic Surfactant	20

WO 98/55093

PCT/US98/10971

45

Head Group Size of Anionic Surfactant	Small
Primary Chain Length of Anionic Surfactant	14-16
Biological Activity (Z) of acid	1.2

The cleansing compositions all have a Gram Positive Residual Effectiveness Index of greater than 1.8, a Gram Negative Residual Effectiveness Index of greater than 0.3, a One-wash Immediate Germ Reduction Index of greater than 2.5, a Ten-wash Immediate Germ Reduction Index of greater than 2.8; and a Mildness Index of greater than 0.3.

Procedure for Making Above Examples

Add all but 5 weight percent water to mix tank. Add surfactants to mix tank. Heat materials to 155°F ±10°F and mix until dissolved. Cool to less than 100°F, add acid, active and perfume. Mix until materials are dissolved. Measure and adjust pH to target with required buffer (NaOH or sodium salt of acid). Add remaining water to complete product.

WO 98/55093

PCT/US98/10971

46

WHAT IS CLAIMED IS:

1. A rinse-off antimicrobial cleansing composition characterized in that it comprises:
 - a. from 0.001% to 5% of an antimicrobial active;
 - b. from 1% to 80% of an anionic surfactant;
 - c. from 0.1% to 12% of a proton donating agent; and
 - d. from 3% to 98.899% of water;wherein the composition is adjusted to a pH of from 3.0 to 6.0;
wherein the rinse-off antimicrobial cleansing composition has a Gram Negative Residual Effectiveness Index of greater than 0.3; and
wherein the rinse-off antimicrobial cleansing composition has a Mildness Index of greater than 0.3.
2. A rinse-off antimicrobial cleansing composition characterized in that it comprises:
 - a. from 0.001% to 5% of an antimicrobial active;
 - b. from 1% to 80% of an anionic surfactant;
 - c. from 0.1% to 12% of a proton donating agent;
 - d. from 1% to 30% of a lipophilic skin moisturizing agent; and
 - e. from 3% to 98.899% of water;wherein the composition is adjusted to a pH of from 3.0 to 6.0;
wherein the rinse-off antimicrobial cleansing composition has a Gram Positive Residual Effectiveness Index of greater than 2.0; and
wherein the rinse-off antimicrobial cleansing composition has a Mildness Index of greater than 0.4.
3. A rinse-off antimicrobial cleansing composition characterized in that it is effective against Gram positive bacteria, Gram negative bacteria, fungi, yeasts, molds and viruses comprising:
 - a. from 0.001% to 5% of an antimicrobial active;
 - b. from 1% to 80% of an anionic surfactant;
 - c. from 0.1% to 12% of a proton donating agent; and
 - d. from 3% to 98.899% of water;wherein the composition is adjusted to a pH of from 3.0 to 6.0;
wherein the rinse-off antimicrobial cleansing composition has a Ten-wash Immediate Germ Reduction Index of greater than 2.8 and

WO 98/55093

PCT/US98/10971

47

wherein the rinse-off antimicrobial cleansing composition has a Mildness Index of greater than 0.3.

4. A rinse-off antimicrobial cleansing composition according to any of the preceding claims wherein the antimicrobial active is selected from the group consisting of Triclosan®, Triclocarban®, Octopirox®, PCMX, ZPT, natural essential oils and their key ingredients, and mixtures thereof.
5. A rinse-off antimicrobial cleansing composition according to any of the preceding claims wherein the anionic surfactant has a solubility slope, K, of less than 0.60 and has a Microtox Index of less than 150.
6. A rinse-off antimicrobial cleansing composition according to any of the preceding claims wherein the anionic surfactant is selected from the group consisting of sodium and ammonium alkyl sulfates and ether sulfates having chain lengths of predominantly 12 and 14 carbon atoms, olefin sulfates having chain lengths of predominantly 14 and 16 carbon atoms, and paraffin sulfonates having an average chain length of from 13 to 17 carbon atoms, and mixtures thereof.
7. A rinse-off antimicrobial cleansing composition according to any of the preceding claims comprising from 5% to 25% of the anionic surfactant.
8. A rinse-off antimicrobial cleansing composition according to any of the preceding claims wherein the proton donating agent is a mineral acid.
9. A rinse-off antimicrobial cleansing composition according to any of Claim 1 through Claim 6 wherein the proton donating agent is an organic acid having a Biological Activity Index, Z, of greater than 0.5.
10. A rinse-off antimicrobial cleansing composition according to Claim 8 wherein the proton donating agent is selected from the group comprising adipic acid, tartaric acid, citric acid,

WO 98/55093

PCT/US98/10971

48

maleic acid, malic acid, succinic acid, glycolic acid, glutaric acid, benzoic acid, malonic acid, salicylic acid, gluconic acid, polyacrylic acid, their salts, and mixtures thereof.

11. A rinse-off antimicrobial cleansing composition according to any of the preceding claims wherein the ratio of the amount of non-anionic surfactants to the amount of anionic surfactant is less than 1:1.
12. A method for providing residual effectiveness against Gram negative bacteria comprising the use of a safe and effective amount of the composition of any of the preceding claims on human skin.
13. A method for treating acne comprising the use of a safe and effective amount of the composition of any of the preceding claims on human skin.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/10971

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K7/50 C11D3/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C11D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 32705 A (UNILEVER PLC ; UNILEVER NV (NL)) 7 December 1995 cited in the application see claims see examples	1-12
Y	US 4 975 217 A (BROWN-SKROBOT SUSAN K ET AL) 4 December 1990 see claim 1; table 8 see column 6, line 35 - column 7, line 3 see column 18, line 6 - line 15 -/-	1-12

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the international search

17 September 1998

Date of mailing of the international search report

24/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

McConnell, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/10971

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 93 17558 A (WHITELEY REGINALD KEITH) 16 September 1993 see page 5, line 8 - page 6, line 21 see page 8, line 26 - page 9, line 20 see page 11, line 9 - page 12, line 5 see page 12, line 16 - line 21 see page 13, line 12 - page 14, line 8 ----	1,3,4,6
A	EP 0 034 846 A (PROCTER & GAMBLE) 2 September 1981 see examples ----	1-4
A	WO 96 17918 A (RABONE KENNETH LESLIE ;ALLAN ALEXANDER (GB); SHARPLES MARTIN (GB);) 13 June 1996 ----	
A	US 3 141 821 A (COMPEAU, G.M.) 21 July 1964 cited in the application -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/10971

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9532705 A	07-12-1995	US 5681802 A	28-10-1997
		AU 2735595 A	21-12-1995
		BR 9507819 A	16-09-1997
		CA 2186011 A	07-12-1995
		CN 1148803 A	30-04-1997
		CZ 9603500 A	14-05-1997
		EP 0762868 A	19-03-1997
		HU 76537 A	29-09-1997
		JP 10500962 T	27-01-1998
		PL 317427 A	14-04-1997
		SK 152596 A	04-06-1997
US 4975217 A	04-12-1990	US 4828912 A	09-05-1989
		AU 554127 B	07-08-1986
		AU 8621082 A	27-01-1983
		BE 893895 A	16-11-1982
		CA 1188225 A	04-06-1985
		DE 3227126 A	03-02-1983
		DK 315482 A	21-01-1983
		FI 822542 A	21-01-1983
		FR 2509577 A	21-01-1983
		GB 2103089 A,B	16-02-1983
		JP 58135802 A	12-08-1983
		LU 84282 A	07-02-1983
		NL 8202885 A	16-02-1983
		SE 8204372 A	19-07-1982
		US 4897304 A	30-01-1990
		ZA 8204975 A	29-02-1984
WO 9317558 A	16-09-1993	AU 662399 B	31-08-1995
		CA 2131289 A	16-09-1993
		EP 0630182 A	28-12-1994
		JP 7506815 T	27-07-1995
		NZ 249441 A	21-12-1995
		US 5610189 A	11-03-1997
EP 0034846 A	02-09-1981	AT 7265 T	15-05-1984
		CA 1150633 A	26-07-1983
		JP 56159295 A	08-12-1981
		US 4470982 A	11-09-1984

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/10971

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9617918 A	13-06-1996	AU 2673395 A	15-01-1996
		AU 689354 B	26-03-1998
		AU 4177296 A	26-06-1996
		BR 9508088 A	12-08-1997
		BR 9509886 A	21-10-1997
		CA 2206771 A	13-06-1996
		CZ 9701744 A	17-06-1998
		EP 0766729 A	09-04-1997
		EP 0796315 A	24-09-1997
		JP 10501832 T	17-02-1998
		PL 317896 A	28-04-1997
		PL 320639 A	13-10-1997
		CA 2189018 A	28-12-1995
		CN 1151180 A	04-06-1997
		WO 9535364 A	28-12-1995
		HU 77302 A	30-03-1998
		SK 71197 A	08-10-1997
		US 5631218 A	20-05-1997
US 3141821 A	21-07-1964	NONE	